<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.0" xml:lang="hr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">lv-145-1</article-id>
<article-id pub-id-type="doi">10.26800/LV-145-1-2-1</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group>
</article-categories>
<title-group>
<article-title>Iskustva s galaktozemijom u Hrvatskoj</article-title>
<trans-title-group xml:lang="en">
<trans-title>Experiences with galactosemia in Croatia</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>&#x0160;maguc</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ramad&#x017E;a</surname><given-names>Danijela Petkovi&#x0107;</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sarnavka</surname><given-names>Vladimir</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kr&#x017E;elj</surname><given-names>Vjekoslav</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lozi&#x0107;</surname><given-names>Bernarda</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pu&#x0161;elji&#x0107;</surname><given-names>Silvija</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Raheli&#x0107;</surname><given-names>Valentina</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mesari&#x0107;</surname><given-names>Nikola</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grubi&#x0107;</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bogdani&#x0107;</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Uroi&#x0107;</surname><given-names>Anita &#x0160;pehar</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>&#x017D;igman</surname><given-names>Tamara</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grizelj</surname><given-names>Ru&#x017E;a</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vukovi&#x0107;</surname><given-names>Jurica</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marde&#x0161;i&#x0107;</surname><given-names>Du&#x0161;ko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Szatmari</surname><given-names>Ildiko</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rivera</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref><xref ref-type="aff" rid="aff11"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fumi&#x0107;</surname><given-names>Ksenija</given-names></name><xref ref-type="aff" rid="aff12"><sup>12</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5119-9174</contrib-id><name><surname>Bari&#x0107;</surname><given-names>Ivo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<aff id="aff1"><label>1</label>Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Zagrebu</aff>
<aff id="aff2"><label>2</label>Klinika za pedijatriju, Klini&#x010D;ki bolni&#x010D;ki centar Zagreb</aff>
<aff id="aff3"><label>3</label>Klinika za pedijatriju, Klini&#x010D;ki bolni&#x010D;ki centar Split</aff>
<aff id="aff4"><label>4</label>Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Splitu</aff>
<aff id="aff5"><label>5</label>Sveu&#x010D;ili&#x0161;ni odjel zdravstvenih studija, Sveu&#x010D;ili&#x0161;te u Splitu</aff>
<aff id="aff6"><label>6</label>Klinika za pedijatriju, Klini&#x010D;ki bolni&#x010D;ki centar Osijek</aff>
<aff id="aff7"><label>7</label>Medicinski fakultet, Sveu&#x010D;ili&#x0161;te Josipa Jurja Strossmayera u Osijeku</aff>
<aff id="aff8"><label>8</label>Slu&#x017E;ba za prehranu i dijetetiku, Klini&#x010D;ki bolni&#x010D;ki centar Zagreb</aff>
<aff id="aff9"><label>9</label><institution>SE I. sz. Gyermekgy&#x00F3;gy&#x00E1;szati Klinika, Anyagcsere Sz&#x0171;r&#x0151; &#x00E9;s Diagnosztikai K&#x00F6;zpont</institution>, <addr-line>Budapest</addr-line>, <country country="hu">Hungary</country></aff>
<aff id="aff10"><label>10</label><italic>Metabolism &amp; Genetics Group, Research Institute for Medicines</italic> (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal</aff>
<aff id="aff11"><label>11</label><institution content-type="dept">Department of Biochemistry and Human Biology, Faculty of Pharmacy</institution>, <institution>Universidade de Lisboa</institution>, <country country="pt">Portugal</country></aff>
<aff id="aff12"><label>12</label>Klini&#x010D;ki zavod za laboratorijsku dijagnostiku, Klini&#x010D;ki bolni&#x010D;ki centar Zagreb</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Adresa za dopisivanje: Prof. dr. sc. Ivo Bari&#x0107;, dr. med., <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-5119-9174">https://orcid.org/0000-0002-5119-9174</ext-link> Klinika za pedijatriju, Klini&#x010D;ki bolni&#x010D;ki centar Zagreb, Ki&#x0161;pati&#x0107;eva 12, 10000 Zagreb; e-po&#x0161;ta: <email xlink:href="ibaric@kbc-zagreb.hr">ibaric@kbc-zagreb.hr</email></corresp>
<fn fn-type="con">
<p content-type="fn-title">DOPRINOS AUTORA</p>
<p>K<sc>oncepcija</sc> <sc>ili</sc> <sc>nacrt</sc> <sc>rada</sc>: IB, A&#x0160;, DPR</p>
<p>Prikupljanje, analiza i interpretacija podataka:</p>
<p>IB, IS, IR, A&#x0160;, DPR, KF, VK, BL, SP, VR, NM, MG, AB, A&#x0160;U, T&#x017D;, RG, JV, DM</p>
<p>P<sc>isanje</sc> <sc>prve</sc> <sc>verzije</sc> <sc>rada</sc>: A&#x0160;, DPR</p>
<p>K<sc>riti&#x010D;ka</sc> <sc>revizija</sc>: A&#x0160;, DPR, KF, A&#x0160;U</p>
</fn>
</author-notes>
<pub-date pub-type="epub-ppub"><month>03</month><year>2023</year></pub-date>
<volume>145</volume>
<issue>1-2</issue>
<fpage>1</fpage>
<lpage>11</lpage>
<permissions>
<copyright-year>2023</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<p>Cilj na&#x0161;eg rada bio je opis osobitosti bolesnika s klasi&#x010D;nom galaktozemijom iz Hrvatske uz prikaz bolesnika s manjkom galaktokinaze i bolesnika koji je dvostruki heterozigot za mutacije gena galaktoza-1-fosfat-uridiltransferaze (<italic>GALT</italic>) i galaktoza-4&#x2019;-epimeraze (<italic>GALE</italic>). Istra&#x017E;ivanje je obuhvatilo 24 bolesnika s dijagnozom klasi&#x010D;ne galaktozemije postavljenom u razdoblju od 1977. do 2020. godine. Dijagnoza je postavljana na temelju klini&#x010D;ke slike, koncentracije galaktoze u krvi i urinu, a potvr&#x0111;ivana mjerenjem aktivnost galaktoza-1-fosfat-uridil-transferaze i/ili analizom gena <italic>GALT</italic>. Simptome u novoro&#x0111;ena&#x010D;kom razdoblju razvilo je 87% bolesnika, a jedan bolesnik je umro. Medijan dobi pri pojavi prvih simptoma bio je &#x010D;etiri dana, a pri po&#x010D;etku dijete jedanaest i pol dana. Barem jednu dugoro&#x010D;nu komplikaciju razvilo je 78,3% bolesnika. Me&#x0111;u njima su bili poreme&#x0107;aji psihomotori&#x010D;kog razvoja (68,2%), pona&#x0161;anja (31,8%) i govora (55,6%), smanjene intelektualne sposobnosti (46,2%), druge neurolo&#x0161;ke komplikacije (40,9%), katarakta (18,2%) i smanjena mineralna gusto&#x0107;a kostiju (27,8%). Zatajenje jajnika razvilo je 66,7% bolesnica starijih od 10 godina. Uspore&#x0111;uju&#x0107;i bolesnike iz iste obitelji, iako je po&#x010D;etak lije&#x010D;enja u drugoro&#x0111;enih bio raniji, &#x010D;ini se da dugoro&#x010D;ne komplikacije nisu bile povezane s redoslijedom ro&#x0111;enja. Ova studija pokazuje da ve&#x0107;ina bolesnika s klasi&#x010D;nom galaktozemijom razvije simptome u novoro&#x0111;ena&#x010D;kom razdoblju i, unato&#x010D; strogom pridr&#x017E;avanju dijete, dugoro&#x010D;ne komplikacije. Mnogi su jo&#x0161; nepoznati &#x010D;imbenici koji utje&#x010D;u na patogenezu i klini&#x010D;ki tijek bolesti, zbog &#x010D;ega su potrebna daljnja istra&#x017E;ivanja klasi&#x010D;ne galaktozemije.</p>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<p>The aim of our study was to describe the characteristics of patients with classical galactosemia in Croatia, with the description of patients with galactokinase deficiency and a patient who was a double heterozygote for mutations of the galactose-1-phosphate uridyl transferase (<italic>GALT</italic>), and galactose-4&#x2019;-epimerase (<italic>GALE</italic>) genes. The study included 24 patients who were diagnosed with classic galactosemia from 1977 to 2020. Diagnosis was based on clinical presentation and galactose concentrations in blood and urine, and confirmed by measuring galactose-1-phosphate-uridyl-transferase activity and/or <italic>GALT</italic> gene analysis. Acute manifestations of the disease developed in 87% of patients in the newborn period, and one patient died. The median age at the onset of first symptoms was four days and for onset of therapy 11.5 days. At least one long-term complication occured in 78.3% of patients, including developmental disorders (68.2%), behavioral disorders (31.8%), speech disorders (55.6%), impaired intellectual abilities (46.2%), other neurological complications (40.9%), cataract (18.2%), and decreased bone mineral density (27.8%). Ovarian insufficiency occured in 66.7% of female patients older than 10 years. When comparing siblings, although a galactose-free diet was started earlier in the second-born children with classical galactosemia, the incidence of long-term outcomes did not appear to be related to birth order. In conclusion, this study shows that the vast majority of patients develop symptoms in the neonatal period, as well as long-term complications, despite strict adherence to a galactose-free diet. Many factors that affect the pathogenesis and clinical course of the disease are still unknown, which is why further research into classical galactosemia is needed.</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori GALAKTOZEMIJA &#x2013; dijagnoza, genetika, komplikacije</kwd><kwd>GALAKTOZA &#x2013; u krvi</kwd><kwd>GALAKTOZA-1-FOSFAT URIDIL TRANSFERAZA &#x2013; genetika, nedostatak</kwd><kwd>URIDIN DIFOSFAT GALAKTOZA 4-EPIMERAZA &#x2013; genetika, nedostatak</kwd><kwd>GALAKTOKINAZA &#x2013; genetika, nedostatak</kwd><kwd>MUTACIJA</kwd><kwd>FENOTIP</kwd><kwd>NOVORO&#x0110;ENA&#x010C;KI PROBIR</kwd><kwd>HRVATSKA</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>GALACTOSEMIAS &#x2013; complications, diagnosis, genetics</kwd><kwd>GALACTOSE &#x2013; blood</kwd><kwd>UTP-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE &#x2013; deficiency, genetics</kwd><kwd>UDP GLUCOSE 4-EPIMERASE &#x2013; deficiency, genetics</kwd><kwd>GALACTOKINASE &#x2013; deficiency, genetics</kwd><kwd>MUTATION</kwd><kwd>PHENOTYPE</kwd><kwd>NEONATAL SCREENING</kwd><kwd>CROATIA</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Galaktozemija je skupina autosomno recesivno nasljednih poreme&#x0107;aja enzima koji sudjeluju u metabolizmu galaktoze, a zajedni&#x010D;ko im je obilje&#x017E;je povi&#x0161;ena koncentracija galaktoze u krvi. Galaktozemija mo&#x017E;e biti uzrokovana mutacijama gena <italic>GALM</italic>, <italic>GALK1</italic>, <italic>GALT</italic> i <italic>GALE</italic> koji kodiraju enzime galaktoza-mutarotazu (GALM), galaktokinazu (GALK), galaktoza-1-fosfat-uridil-transferazu (GALT) odnosno galaktoza-4&#x2019;-epimerazu (GALE). (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r2"><italic>2</italic></xref>)</p>
<p>Galaktozemija tipa I (klasi&#x010D;na galaktozemija) naj&#x010D;e&#x0161;&#x0107;a je vrsta galaktozemije s incidencijom od 1: 30.000 do 1: 1.000.000 &#x017E;ivoro&#x0111;enih. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>, <xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) Zbog nedostatne aktivnosti enzima GALT dolazi do nakupljanja galaktoza-1-fosfata koji je u novoro&#x0111;ena&#x010D;koj i dojena&#x010D;koj dobi toksi&#x010D;an ponajprije za jetru, ali i za bubrege i mozak. Nakuplja se i galaktitol, &#x0161;to uzrokuje stvaranje katarakte. Ako novoro&#x0111;en&#x010D;e u hrani prima laktozu, koja se u crijevu razgra&#x0111;uje u glukozu i galaktozu, bolest se klini&#x010D;ki o&#x010D;ituje naj&#x010D;e&#x0161;&#x0107;e ve&#x0107; u novoro&#x0111;ena&#x010D;kom razdoblju. Novoro&#x0111;en&#x010D;ad odbija hranu, ne napreduje ili gubi na tjelesnoj masi, povra&#x0107;a, ima u razli&#x010D;itim kombinacijama, ovisno i o uznapredovalosti bolesti, proljev, &#x017E;uticu, ascites, edeme, hepatomegaliju, kataraktu, letargi&#x010D;na je i hipotoni&#x010D;na. &#x010C;esta je sklonost infekcijama, osobito sepsi uzrokovanoj <italic>E. coli</italic>. Rje&#x0111;e se javlja pseudotumor mozga. Ako se pravodobno ne lije&#x010D;i, mo&#x017E;e do&#x0107;i do smrti. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) Dijeta bez laktoze sprje&#x010D;ava razvoj simptoma, odnosno ako je zapo&#x010D;eta nakon &#x0161;to su se oni pojavili i ako bolest nije u&#x0161;la u stadij ireverzibilnosti dovodi do njihovog povla&#x010D;enja uz potpuni oporavak funkcije jetre. Zbog zna&#x010D;ajne endogene sinteze galaktoze, bezmlije&#x010D;na dijeta ne rezultira normalizacijom galaktoza-1-fosfata i to je jedan od mogu&#x0107;ih uzroka dugoro&#x010D;nih komplikacija ove bolesti. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) Naj&#x010D;e&#x0161;&#x0107;e dugoro&#x010D;ne komplikacije jesu poreme&#x0107;aji rasta, psihomotori&#x010D;kog razvoja, govora, kognitivnih i drugih neurolo&#x0161;kih funkcija, smanjena mineralna gusto&#x0107;a kostiju i katarakta, a u &#x017E;ena zatajenje jajnika. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>) Stoga se, uz ubla&#x017E;avanje dijete u odrasloj dobi, (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>, <xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) istra&#x017E;uju novi terapijski pristupi poput inhibitora galaktokinaze, (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>) antioksidansa, (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) molekula pratitelja, (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) glasni&#x010D;ke RNK (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) i terapija protusmjernim (od engl. <italic>antisense</italic>) oligonukleotidima (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>). U nekim populacijama je razmjerno &#x010D;esta, do oko 1: 4.000 &#x017E;ivoro&#x0111;enih, biokemijska ili varijanta Duarte koja je povezana s mutacijom c.940A&gt;G (p.N314D). (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>, <xref ref-type="bibr" rid="r17"><italic>17</italic></xref>) Osobe s varijantom Duarte zbog ostatne aktivnosti enzima nemaju simptome u novoro&#x0111;ena&#x010D;kom razdoblju niti dugoro&#x010D;ne komplikacije. (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>&#x2013;<xref ref-type="bibr" rid="r20"><italic>20</italic></xref>)</p>
<p>Manjak GALK-a (galaktozemija tipa II), rje&#x0111;i je od klasi&#x010D;ne galaktozemije, s incidencijom od 1: 150.000 do 1: 1.000.000 &#x017E;ivoro&#x0111;enih. (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>) &#x010C;e&#x0161;&#x0107;i je u romskoj populaciji. Glavno je klini&#x010D;ko obilje&#x017E;je pojava obostrane katarakte. Rje&#x0111;e se opisuje pseudotumor mozga. &#x010C;ini se da su u novoro&#x0111;ena&#x010D;koj dobi &#x010D;e&#x0161;&#x0107;i nego u zdravoj populaciji encefalopatija, hemoragijska dijateza i povi&#x0161;enje aminotransferaza, a upitno je je li to slu&#x010D;aj s kognitivnim i motori&#x010D;kim razvojem. (<xref ref-type="bibr" rid="r22"><italic>22</italic></xref>&#x2013;<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>) Pravodobno zapo&#x010D;eta bezmlije&#x010D;na dijeta omogu&#x0107;uje sprje&#x010D;avanje, a &#x010D;esto i regresiju katarakte. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>)</p>
<p>Nedostatna aktivnost enzima GALE (galaktozemija tipa III) kontinuum je triju oblika bolesti: perifernog, intermedijarnog i generaliziranog. (<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>) Incidencija perifernog i intermedijarnog oblika jest 1: 70.000, dok je generalizirani iznimno rijedak. U perifernom obliku aktivnost enzima nedostatna je u eritrocitima i cirkuliraju&#x0107;im leukocitima. Bolesnici su uz prehranu mlijekom bez simptoma. Intermedijarni oblik ima smanjenu aktivnost i u ostalim tkivima, ali ve&#x0107;u od 50% normalne. Novoro&#x0111;en&#x010D;ad je uz prehranu mlijekom bez simptoma. &#x010C;ini se da bezmlije&#x010D;na dijeta u novoro&#x0111;ena&#x010D;kom razdoblju sprje&#x010D;ava nastanak kasnijih komplikacija poput poreme&#x0107;aja u psihomotori&#x010D;kom razvoju. Aktivnost enzima je u generaliziranom obliku znatno smanjena u svim tkivima. Simptomi i znakovi u novoro&#x0111;ena&#x010D;kom razdoblju nalikuju onima u klasi&#x010D;noj galaktozemiji, a tako&#x0111;er se sprje&#x010D;avaju i lije&#x010D;e dijetom bez galaktoze. Opisane su dugoro&#x010D;ne komplikacije poput poreme&#x0107;aja psihomotori&#x010D;kog razvoja i u&#x010D;enja, zamjedbenog gubitka sluha i kardiomiopatije. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>, <xref ref-type="bibr" rid="r27"><italic>27</italic></xref>)</p>
<p>Galaktozemija tipa IV uzrokovana je nedostatnom aktivnosti enzima GALM. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) Procijenjena incidencija &#x0161;iroko varira od 1: 10.000 do 1: 1.700.000. (<xref ref-type="bibr" rid="r28"><italic>28</italic></xref>) Glavno je obilje&#x017E;je obostrana katarakta koja se sprje&#x010D;ava, a &#x010D;esto i povla&#x010D;i dijetom bez galaktoze. Procjena prirodnog tijeka bolesti i razvoja dugoro&#x010D;nih komplikacija jest nepotpuna. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>)</p>
<p>Povi&#x0161;enu koncentraciju galaktoze u krvi mogu uzrokovati i portosistemski &#x0161;antovi, portalna hipoplazija, otvoreni venozni duktus, tumori jetre, jetrena hemangiomatoza, hepatitis, manjak citrina i Fanconi-Bickelov sindrom. Prolazna novoro&#x0111;ena&#x010D;ka hipergalaktozemija &#x010D;esto je nepoznate etiologije, a mo&#x017E;e biti uzrokovana odgo&#x0111;enim zatvaranjem venoznog duktusa te se mo&#x017E;e razviti u heterozigotnih nosilaca mutacija gena <italic>GALT</italic>, <italic>GALK1</italic>, <italic>GALE</italic> i <italic>GALM</italic>. (<xref ref-type="bibr" rid="r27"><italic>27</italic></xref>, <xref ref-type="bibr" rid="r29"><italic>29</italic></xref>, <xref ref-type="bibr" rid="r30"><italic>30</italic></xref>)</p>
<p>Dijagnosti&#x010D;ki postupak kod svih poreme&#x0107;aja metabolizma galaktoze temelji se na klini&#x010D;kom prepoznavanju simptoma i tijeka bolesti, &#x0161;to uklju&#x010D;uje prepoznavanje perioda latencije prije pojave prvih simptoma i znakova bolesti. Biokemijski, dijagnozu podupiru pozitivne reduktivne tvari u urinu, &#x0161;to nije specifi&#x010D;an nalaz, i povi&#x0161;ena koncentracija galaktoze u krvi i urinu. U Hrvatskoj se trenutno ne mjere galaktitol, koji je povi&#x0161;en kod svih poreme&#x0107;aja metabolizma galaktoze, i galaktoza-1-fosfat, koji je povi&#x0161;en u krvi bolesnika s nedostatnom aktivnosti enzima GALT i GALE. Za potvrdu dijagnoze mjeri se aktivnost enzima u eritrocitima i provodi genska analiza. (<xref ref-type="bibr" rid="r31"><italic>31</italic></xref>) Za razlikovanje tipa poreme&#x0107;aja enzima GALE mogu&#x0107;e je dodatno mjerenje aktivnosti enzima u fibroblastima ili limfoblastima. (<xref ref-type="bibr" rid="r27"><italic>27</italic></xref>) Ako je galaktozemija uklju&#x010D;ena u program novoro&#x0111;ena&#x010D;kog probira, na pozitivan rezultat probira upu&#x0107;uje povi&#x0161;ena koncentracija galaktoze i/ili galaktoza-1-fosfata ili sni&#x017E;ena aktivnost GALT-a u uzorku suhe kapi krvi na filtarskom papiru. Novoro&#x0111;en&#x010D;ad s klasi&#x010D;nom galaktozemijom ima povi&#x0161;ene koncentracije galaktoze i navedenih metabolita te potpuni ili skoro potpuni nedostatak aktivnosti enzima GALT, dok novoro&#x0111;en&#x010D;ad s varijantom Duarte ima zna&#x010D;ajnu ostatnu aktivnost enzima. (<xref ref-type="bibr" rid="r32"><italic>32</italic></xref>)</p>
<p>Cilj rada bio je opis osobitosti bolesnika iz Hrvatske s klasi&#x010D;nom galaktozemijom uz prikaz bolesnika s manjkom galaktokinaze i bolesnika koji kao dvostruki heterozigot za mutacije gena <italic>GALT</italic> i <italic>GALE</italic> ilustrira dio mogu&#x0107;ih dvojbi u dijagnostici dojen&#x010D;adi s bolesti jetre i hipergalaktozemijom.</p>
<sec sec-type="other1">
<title>Bolesnici i metode</title>
<p>Studija je uklju&#x010D;ila 24 bolesnika s dijagnozom klasi&#x010D;ne galaktozemije postavljenom u razdoblju od 1977. do 2020. godine koji su obra&#x0111;ivani, pra&#x0107;eni ili lije&#x010D;eni u Zavodu za genetiku i bolesti metabolizma i/ili u Metaboli&#x010D;koj ambulanti Klinike za pedijatriju Klini&#x010D;koga bolni&#x010D;kog centra Zagreb. Kao izvori podataka pregledani su bolni&#x010D;ka arhiva, bolni&#x010D;ki informacijski sustav i ambulantne povijesti bolesti. Podatci su prikupljani s osvrtom na dob pri razvoju simptoma, postavljanju dijagnoze i po&#x010D;etku terapije, na&#x010D;in postavljanja dijagnoze, klini&#x010D;ku sliku u novoro&#x0111;ena&#x010D;koj dobi, laboratorijske nalaze pri po&#x010D;etnom klini&#x010D;kom pogor&#x0161;anju, gensku analizu, dugoro&#x010D;ne komplikacije, lije&#x010D;enje i redovitost kontrole. Zatajenje jetre definiralo se prema kriterijima PALF (od engl. <italic>pediatric acute liver failure</italic>). (<xref ref-type="bibr" rid="r33"><italic>33</italic></xref>) Kada podatci o protrombinskom vremenu ili INR-u nisu bili poznati, kao zamjenski kriterij koristio se protrombinski indeks manji od 0,7. Dijagnoza osteoporoze, prema preporukama ISCD-a (od engl. <italic>International Society for Clinical Densitometry</italic>) za djecu, temeljila se na podatcima o zna&#x010D;ajnim prijelomima kostiju te Z-vrijednostima mineralne gusto&#x0107;e kostiju &#x2264; &#x2013;2,0. (<xref ref-type="bibr" rid="r34"><italic>34</italic></xref>) Dijagnoza osteoporoze u na&#x0161;ih se bolesnika nije koristila budu&#x0107;i da nisu zabilje&#x017E;eni podatci o klini&#x010D;ki zna&#x010D;ajnim frakturama. Stoga su, &#x0161;to se ti&#x010D;e smanjene mineralne gusto&#x0107;e kostiju, statisti&#x010D;ki prikazani samo oni bolesnici koji su imali Z-vrijednosti od &#x2264; &#x2013;2,0. Za detekciju smanjene tjelesne mase i visine uzeti su podatci u tre&#x0107;oj i &#x010D;etvrtoj godini &#x017E;ivota kako bi pro&#x0161;lo dovoljno vremena za oporavak bolesnika u slu&#x010D;aju da su gubili na tjelesnoj masi ili nisu napredovali zbog bolesti u novoro&#x0111;ena&#x010D;kom razdoblju. Za analizu podataka kori&#x0161;tene su metode deskriptivne statistike (medijan, raspon) u programu <italic>Excel 2007 &#x2013; Microsoft</italic>&#x00AE;.</p>
</sec>
<sec sec-type="other2">
<title>Rezultati</title>
<p>Ispitanika mu&#x0161;kog spola bilo je 54,2% (13/24), a &#x017E;enskog 45,8% (11/24). Medijan sada&#x0161;nje dobi bio je 16,6 godina s rasponom od &#x0161;est mjeseci do 42 godine.</p>
<p>Genska osnova ispitanika i aktivnost enzima GALT za odre&#x0111;eni genotip prikazane su u <xref ref-type="table" rid="t1">Table 1</xref>. Dio rezultata analize gena <italic>GALT</italic> u na&#x0161;ih bolesnika ve&#x0107; su opisali Petkovi&#x0107; Ramad&#x017E;a i suradnici. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>) Aktivnost enzima GALT mjerena je u 62,5% (15/24) ispitanika, od &#x010D;ega je u 60% (9/15) bila nemjerljiva. Za dva ispitanika s nemjerljivom aktivno&#x0161;&#x0107;u enzima genotip nije bio poznat.</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Genetic basis and activity of GALT enzyme in patients with classical galactosemia<sup><sc>a</sc></sup></title>
</caption>
<table frame="hsides" rules="groups">
<col width="28.41%"/>
<col width="39.05%"/>
<col width="32.54%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Mutacije gena GALT / Mutations of GALT gene (20/24)<sup>b</sup></th>
<th valign="middle" colspan="2" align="left" scope="colgroup" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Postotak i udio pojedinih mutacija u ukupnom broju analiziranih alela / Percentage and proportion of single mutations in the total number of analyzed alleles</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">c.855G&gt;T (p.K285N)</td>
<td valign="middle" colspan="2" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">40% (16/40)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">c.563A&gt;G (p.Q188R)</td>
<td valign="middle" colspan="2" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">40% (16/40)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">c.367C&gt;T (p.R123X)</td>
<td valign="middle" colspan="2" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">17,5% (7/40)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">c.812G&gt;C (p.E271D)</td>
<td valign="middle" colspan="2" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">2,5% (1/40)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Genotipovi / Genotypes (20/24)<sup>b</sup></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Postotak i udio pojedinih genotipova u ukupnom broju genotipova / Percentage and proportion of single genotypes in the total number of genotypes</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Aktivnost enzima GALT / Activity of GALT enzyme (15/24)<sup>b</sup></td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">c.563A&gt;G / c.855G&gt;T</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">25% (5/20)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">N (1/15), 0,25 &#x00B5;kat/gHb<sup>c</sup> (1/15), 2% (1/15)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">c.563A&gt;G / c.563A&gt;G</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">20% (4/20)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">N (1/15), 2,15<sup>d</sup> (1/15)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">c.855G&gt;T / c.855G&gt;T</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">20% (4/20)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">N (3/15)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">c.367C&gt;T / c.563A&gt;G</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">15% (3/20)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0,13 &#x2013; 0,14 U/gHb<sup>e</sup> (2/15)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">c.367C&gt;T / c.855G&gt;T</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">10% (2/20)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0,0 &#x2013; 0,83 U/gHb<sup>e</sup> (2/15)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">c.367C&gt;T / c.367C&gt;T</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">5% (1/20)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Nepoznatno / Unknown</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">c.855G&gt;T / c.812G&gt;C</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">5% (1/20)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">N (1/15)</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p><sup>a</sup> Dio rezultata analize gena <italic>GALT</italic> u na&#x0161;ih bolesnika ve&#x0107; su opisali Petkovi&#x0107; Ramad&#x017E;a i suradnici. / Results of <italic>GALT</italic> gene analysis have partly been already published by Petkovi&#x0107; Ramad&#x017E;a et al. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>) Broj ispitanika za koje su podatci bili poznati / number of patients for whom the data were known; U zdravoj populaciji / in healthy population: <sup>c</sup> &gt; 0,3 &#x00B5;kat/gHb, <sup>d</sup> &gt; 4, <sup>e</sup> 2,3 &#x2013; 25 U/gHb, N &#x2013; nemjerljivo / immeasurable</p>
</table-wrap-foot></table-wrap>
<p>Simptomi u novoro&#x0111;ena&#x010D;kom razdoblju bili su poznati za 95,8% (23/24) ispitanika. Za jednu bolesnicu, koja je imala pozitivnu obiteljsku anamnezu, kao izvor podataka postoji samo jedan ambulantni nalaz u dobi od sedam i pol godina, zbog &#x010D;ega za nju nisu obra&#x0111;eni podatci o novoro&#x0111;ena&#x010D;kom razdoblju. Jednom ispitaniku koji je lije&#x010D;en u inozemstvu dijagnoza je postavljena i dijeta zapo&#x010D;eta u dojena&#x010D;koj dobi s nepoznatom to&#x010D;nom dobi. Simptome nije imalo 13% (3/23) ispitanika koji su svi imali pozitivnu obiteljsku anamnezu. Dvije bolesnice koje su imale pozitivnu obiteljsku anamnezu imale su simptome u novoro&#x0111;ena&#x010D;kom razdoblju. Jedan bolesnik je umro u dobi od &#x0161;est tjedana.</p>
<p>Medijan dobi pri razvoju prvih simptoma u ispitanika za koje su ti podatci bili poznati (n = 19) bio je &#x010D;etiri dana s rasponom 2 &#x2013; 42 dana.</p>
<p>Medijan dobi pri postavljanju dijagnoze za ispitanike bez pozitivne obiteljske anamneze (94,4%, 17/18) bio je 14 dana s rasponom do 150 dana. Dijagnoza u pacijenata s pozitivnom obiteljskom anamnezom (83,3%, 5/6) postavljena je ubrzo nakon ro&#x0111;enja, s izuzetkom jedne pacijentice kojoj je dijagnoza postavljena 53. dana &#x017E;ivota.</p>
<p>Medijan dobi pri po&#x010D;etku dijete bez galaktoze za ispitanike bez pozitivne obiteljske anamneze (94,4%, 17/18) bio je 14 dana s rasponom do 150 dana. Medijan dobi pri po&#x010D;etku dijete bez galaktoze za ispitanike s pozitivnom obiteljskom anamnezom (83,3%, 5/6) bio je 0 dana s rasponom do 53 dana.</p>
<p>Na&#x010D;in postavljanja dijagnoze bio je poznat za sve ispitanike. Obiteljska anamneza bila je pozitivna u 25% (6/24), klini&#x010D;ka slika karakteristi&#x010D;na za klasi&#x010D;nu galaktozemiju u 83,3% (20/24), a koncentracije galaktoze u krvi i/ili urinu indikativne za klasi&#x010D;nu galaktozemiju u 62,5% (15/24) ispitanika. Pokusni obrok galaktoze proveo se u 20,8% (5/24), mjerenje aktivnosti enzima GALT u eritrocitima u 62,5% (15/24), a genska analiza u 83,3% (20/24) ispitanika.</p>
<p>Dijeta bez galaktoze bila je uvedena svim ispitanicima pri sumnji na klasi&#x010D;nu galaktozemiju.</p>
<p>Obilje&#x017E;ja klini&#x010D;ke slike u novoro&#x0111;ena&#x010D;kom razdoblju u bolesnika bez pozitivne obiteljske anamneze navedena su u <xref ref-type="table" rid="t2">Table 2</xref>. Dvije bolesnice koje su imale simptome, a imale su pozitivnu obiteljsku anamnezu, u klini&#x010D;koj slici imale su: poreme&#x0107;eno op&#x0107;e stanje, povra&#x0107;anje, nenapredovanje na tjelesnoj masi, odbijanje hrane, &#x017E;uticu, ascites, hepatomegaliju, koagulopatiju, somnolenciju, hipotoniju, cerebralne napadaje, infekcije uzrokovane <italic>E. coli</italic> i drugim uzro&#x010D;nicima. Biokemijske nalaze simptomatskih bolesnika pri po&#x010D;etnom klini&#x010D;kom pogor&#x0161;anju prikazuje <xref ref-type="table" rid="t3">Table 3</xref>.</p>
<table-wrap id="t2" position="float">
<label>Table 2</label><caption><title>Characteristics of clinical presentation in neonatal period in patients without a positive family history (n = 18)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="65.85%"/>
<col width="34.15%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Simptomi i znakovi bolesti / Signs and symptoms</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Postotak i udio simptoma i znakova / Proportion and percentage of symptoms and signs</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Zatajenje jetre i/ili hepatopatija / Liver failure and/or hepatopathy</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">100% (18/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Poreme&#x0107;eno op&#x0107;e stanje / Disturbed general condition</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">83,3% (15/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Koagulopatija / Coagulopathy</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">66,7% (12/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">&#x017D;utica / Jaundice</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">61,1% (11/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Infekcije uzro&#x010D;nicima koji nisu <italic>E. coli</italic> / Infections with microbes other than <italic>E. coli</italic></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">55,6% (10/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Hipotonija / Hypotonia</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">50% (9/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Gubitak na tjelesnoj masi i/ili nenapredovanje / Weight loss and/or failure to thrive</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">50% (9/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Infekcija uzrokovana <italic>E. coli</italic> / <italic>E. coli</italic> infection</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">44,4% (8/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Poreme&#x0107;aj svijesti (somnolencija) / Disturbed consciousness (somnolence)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">38,9% (7/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Sepsa / Sepsis<break/>&#x00A0;&#x00A0;&#x2013; <italic>E. coli</italic> sepsa / <italic>E. coli</italic> sepsis</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">38,9% (7/18)<break/>71,4% (5/7)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Povra&#x0107;anje i/ili poja&#x010D;ano bljuckanje / Vomiting and/or increased regurgitation</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">33,3% (6/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Katarakta / Cataract</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">33,3% (6/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Smanjena spontana motorika / Reduced spontaneous movements</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">22,2% (4/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Pove&#x0107;an opseg glave<sup>a</sup> / Increased head circumference<sup>a</sup></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">16,7% (3/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Ascites / Ascites</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">11,1% (2/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Odbijanje hrane / Food refusal</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">11,1% (2/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Opistotonus / Opisthotonus</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">11,1% (2/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Distonija / Dystonia</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">11,1% (2/18)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Cerebralni napadaji / Seizures</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">5,6% (1/18)</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p><sup>a</sup> iznad 97. percentile za dob / above the 97<sup>th</sup> percentile for age</p>
</table-wrap-foot></table-wrap>
<table-wrap id="t3" position="float">
<label>Table 3</label><caption><title>Biochemical findings in the initial clinical deterioration of symptomatic patients without (&#x2013; OA) and with (+ OA) positive family history</title>
</caption>
<table frame="hsides" rules="groups">
<col width="33.16%"/>
<col width="17.75%"/>
<col width="8.27%"/>
<col width="11.83%"/>
<col width="28.99%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Analit / Analyte (Referentne vrijednosti su u zagradama / Reference values are in parentheses)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Obiteljska anamneza / Family history</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Medijan / Median</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Raspon / Range</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Postotak bolesnika s nalazom izvan referentnog raspona / Percentage of patients with findings outside reference range</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Galaktoza u krvi / Blood galactose (&lt; 300 &#x00B5;mol/L)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">2295</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">323,4 &#x2013; 9597</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">100% (9/9)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">508</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">243 &#x2013; 773</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">50% (1/2)</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Galaktoza u urinu / Urine galactose (&lt; 1665 &#x00B5;mol/L)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">5778</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">334 &#x2013; 49733</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">85,7% (6/7)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">437</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">101 &#x2013; 773</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0% (0/2)</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Protrombinski indeks / Prothrombin index (&gt; 0,7)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,14</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,05 &#x2013; 0,5</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">100% (10/10)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,50</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,50</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">100% (1/1)</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">PV INR / PT INR (&lt; 1,1)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">3,74</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1,5 &#x2013; 5,18</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">100% (4/4)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">/</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">APTV / APPT (&lt; 59 s)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">113,9</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">83,6 &#x2013; 124,6</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">100% (6/6)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">/</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Fibrinogen (1,25 &#x2013; 3 g/L)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,8</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,49 &#x2013; 1,5</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">85,7% (6/7)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">/</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Glukoza u krvi, najni&#x017E;e vrijednosti / Blood glucose, lowest values<break/>(2,8 &#x2013; 5 mmol/L)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">2,9</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1,8 &#x2013; 4,1</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">44,4% (4/9)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">/</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">AST (26 &#x2013; 75 U/L)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">130</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">59 &#x2013; 660</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">92,3% (12/13)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">119</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">57 &#x2013; 181</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">50% (1/2)</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">ALT (11 &#x2013; 46 U/L)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">78</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">27 &#x2013; 225</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">84,6% (11/13)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">53</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">30 &#x2013; 76</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">50% (1/2)</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">GGT (13 &#x2013; 147 U/L)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">87</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">14,8 &#x2013; 208</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">45,5% (5/11)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">8</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">6 &#x2013; 10</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0% (0/2)</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Bilirubin, ukupni / Total bilirubin (11,7 &#x2013; 205 &#x00B5;mol/L)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">340,8</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">90,6 &#x2013; 616</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">76,9% (10/13)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">179,2</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">80,4 &#x2013; 278</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">50% (1/2)</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Bilirubin, konjugirani / Conjugated bilirubin (&lt; 35 &#x00B5;mol/L)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">59</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">11 &#x2013; 134</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">88,9% (8/9)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">/</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Omjer konjugiranog i ukupnog bilirubina / Conjugated to total bilirubin ratio (&lt; 0,2)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,27</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,06 &#x2013; 0,5</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">55,6% (5/9)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">/</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Fosfor / Phosphorus (1,4 &#x2013; 3 mmol/L)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1,34</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1,1 &#x2013; 1,73</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">62,5% (5/8)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">/</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">/</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Alkalna fosfataza / Alkaline phosphatase (25* &#x2013; 500 U/L)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">631</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">260 &#x2013; 1101</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">75% (9/12)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">37</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">37</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0% (0/1)</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Pozitivne reduktivne tvari u urinu / Positive reducing substances in urine</td>
<td valign="middle" colspan="3" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&#x2013; OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">80% (8/10)</td>
</tr>
<tr>
<td valign="middle" colspan="3" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">+ OA</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">100% (2/2)</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p>/ &#x2013; nepoznato / unknown, * najni&#x017E;a od razli&#x010D;itih donjih granica referentnog raspona / * the lowest of different lower limits of reference ranges</p>
</table-wrap-foot></table-wrap>
<p>Pokusni obrok galaktoze provodio se u kontroliranim uvjetima u ispitanika dobroga op&#x0107;eg stanja. Nakon jednog ili dva mlije&#x010D;na obroka mjerila se koncentracija galaktoze u serumu i/ili urinu. Povi&#x0161;ene koncentracije (galaktoza u krvi &gt; 300 &#x00B5;mol/L, a u urinu &gt; 1665 &#x00B5;mol/L) podupirale su sumnju na galaktozemiju. Raspon koncentracija galaktoze u krvi nakon pokusnog obroka u na&#x0161;ih bolesnika bio je 303 &#x2013; 2880 &#x00B5;mol/L, a u urinu 550 &#x2013; 8126 &#x00B5;mol/L.</p>
<p>Kao ilustraciju mogu&#x0107;ih te&#x0161;ko&#x0107;a u postavljanju dijagnoze klasi&#x010D;ne galaktozemije navodimo primjer na&#x0161;eg bolesnika upu&#x0107;enog u Kliniku u dobi od mjesec dana zbog konjugirane &#x017E;utice opa&#x017E;ene &#x010D;etiri dana prije primitka, hepatocelularne lezije i zatajenja sintetske funkcije jetre. Obradom je na&#x0111;ena vi&#x0161;estruko povi&#x0161;ena koncentracija galaktoze u krvi i urinu. Aktivnost GALT-a nije dala jednozna&#x010D;ne rezultate (75% od normalne aktivnosti u prvom i 10% u ponovljenom mjerenju). Zato su u&#x010D;injene analize gena <italic>GALT</italic> (na&#x0111;ena je varijanta Duarte 2 u heterozigotnom obliku p.N314D + c.-119_-116del GTCA + c.378-27G&gt;C + c.508-24C&gt;A) i gena <italic>GALE</italic> (intronska varijanta c.873+13G&gt;A nepoznate patogenosti) kojima nisu na&#x0111;ene patogene varijante na oba alela istog gena. Sekvenciranje cijelog egzoma tako&#x0111;er nije otkrilo uzrok bolesti. Zbog progresije bolesti usprkos dijeti bez galaktoze i drugih mjera lije&#x010D;enja dje&#x010D;aku je transplantirana jetra. Ostalo je otvoreno pitanje mo&#x017E;e li i, ako mo&#x017E;e, u kojoj mjeri istovremeno postojanje dviju varijanti koje svaka za sebe mijenjaju ili potencijalno mijenjaju aktivnosti dvaju enzima u razgradnji galaktoze pridonijeti bolesti jetre.</p>
<p><xref ref-type="table" rid="t4">Table 4</xref> prikazuje dugoro&#x010D;ne komplikacije u na&#x0161;ih bolesnika. Pri tuma&#x010D;enju njihove u&#x010D;estalosti u obzir treba uzeti dob bolesnika pri zadnjoj kontroli. Troje bolesnika je tada bilo mla&#x0111;e od godine dana, jo&#x0161; troje mla&#x0111;e od pet godina i jo&#x0161; petero mla&#x0111;e od deset godina.</p>
<table-wrap id="t4" position="float">
<label>Table 4</label><caption><title>Long-term complications in patients with classical galactosemia</title>
</caption>
<table frame="hsides" rules="groups">
<col width="73.18%"/>
<col width="26.82%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Poreme&#x0107;aji psihomotori&#x010D;kog razvoja / Developmental disorders</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">68,2% (15/22)<sup>a</sup></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Poreme&#x0107;aji pona&#x0161;anja i socijalne prilagodbe / Behavioral and social disorders</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">31,8% (7/22)<sup>a</sup></td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Smanjene intelektualne sposobnosti / Decreased intellectual abilities<sup>b</sup></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">46,2% (6/13)<sup>a</sup></td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Pote&#x0161;ko&#x0107;e u &#x0161;kolovanju / Educational difficulties<sup>c</sup></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">73,3% (11/15)<sup>a</sup></td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Poreme&#x0107;aji govora / Speech disorders<sup>d</sup></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">55,6% (10/18)<sup>a</sup></td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Druge neurolo&#x0161;ke komplikacije / Other neurological complications<sup>e</sup></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">40,9% (9/22)<sup>a</sup></td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Katarakta / Cataract</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">18,2% (4/22)<sup>a</sup></td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Zatajenje jajnika / Ovarian insufficiency<sup>f</sup></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">66,7% (4/6)<sup>a</sup></td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Smanjena mineralna gusto&#x0107;a kostiju / Reduced mineral bone density<sup>g</sup></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">27,8% (5/18)<sup>a</sup></td>
</tr>
</tbody>
</table><table-wrap-foot>
<p><sup>a</sup> broj ispitanika za koje su podatci bili poznati / number of patients for whom the data were known, <sup>b</sup> za starije od 2,5 godine / for those older than 2.5 years, <sup>c</sup> za starije od 6 godina / for those older than 6 years, <sup>d</sup> za starije od jedne godine / for those older than 1 year, <sup>e</sup> u tekstu se navodi o kojim je komplikacijama rije&#x010D; / involved complications are stated in the text, <sup>f</sup> za djevojke starije od 10 godina / for girls older than 10 years, <sup>g</sup> za starije od tri godine / for those older than 3 years</p>
</table-wrap-foot></table-wrap>
<p>Poreme&#x0107;aji psihomotori&#x010D;kog razvoja bili su: hipertonija (27,3%, 6/22), usporen psihomotori&#x010D;ki razvoj (18,2%, 4/22), poreme&#x0107;aji percepcije (13,6%, 3/22) te sporije reakcije, hipotonija, distonija i opistotonus (4,5%, 1/22). Vje&#x017E;be razvojne gimnastike trebalo je 36,4% (8/22) ispitanika.</p>
<p>Poreme&#x0107;aji pona&#x0161;anja i socijalne prilagodbe bili su: emocionalna nezrelost (18,2%, 4/22), poreme&#x0107;aji pa&#x017E;nje (13,6%, 3/22), labilnost i negativizam (9,1%, 2/22) te poreme&#x0107;aj pa&#x017E;nje s hiperaktivno&#x0161;&#x0107;u, anksioznost, poreme&#x0107;aji reakcija i afekta, poreme&#x0107;aji komunikacije, stereotipije i potreba za potporom u socijalnom funkcioniranju (4,5%, 1/22).</p>
<p>Od &#x0161;estero bolesnika s intelektualnom onesposobljeno&#x0161;&#x0107;u, te&#x0161;ku intelektualnu onesposobljenost imalo je 66,7% (4/6), umjerenu intelektualnu onesposobljenost 16,7% (1/6) i laku intelektualnu onesposobljenost 16,7% (1/6) bolesnika. Jedan bolesnik s te&#x0161;kom intelektualnom onesposobljeno&#x0161;&#x0107;u u novoro&#x0111;ena&#x010D;kom je razdoblju prebolio meningitis uzrokovan s <italic>E. coli</italic>. Sedam ispitanika bilo je u skupini normalnih intelektualnih sposobnosti. Ispitanici su testirani od 3. do 19. godine &#x017E;ivota.</p>
<p>Pote&#x0161;ko&#x0107;e u &#x0161;kolovanju bile su: poreme&#x0107;aji grafomotorike, potrebna pomo&#x0107; u nastavi, &#x0161;kolovanje po prilago&#x0111;enom programu, te&#x0161;ko&#x0107;e u&#x010D;enja i ra&#x010D;unanja (33,3%, 5/15) te te&#x0161;ko&#x0107;e &#x010D;itanja i poreme&#x0107;aji pam&#x0107;enja (13,3%, 2/15).</p>
<p>Poreme&#x0107;aji govora bili su: sporiji i/ili slabiji razvoj govora (50%, 9/18), dislalija i ote&#x017E;ano razumljiv govor (22,2%, 4/18), oskudnost govora i/ili vokabulara (16,7%, 3/18), usporen govor i poreme&#x0107;aji gramati&#x010D;kog razvoja (11,1%, 2/18), disartrija (5,6%, 1/18). Logopedske vje&#x017E;be polazilo je 38,9% (7/18) ispitanika.</p>
<p>Druge neurolo&#x0161;ke komplikacije bile su: cerebralni napadaji (22,7%, 5/22), poreme&#x0107;aji ravnote&#x017E;e i tremor (18,2%, 4/22), dismetrija i ataksija (13,6%, 3/22), disdijadohokineza (9,1%, 2/22). Jedna bolesnica imala je i diskineziju, hemiparezu, neuropatiju o&#x010D;nog &#x017E;ivca i polineuropatiju. Smanjena mijelinizacija na magnetskoj rezonanciji ili kompjutoriziranoj tomografiji bila je u 13,6% (3/22) ispitanika.</p>
<p>Od devet bolesnica generativne dobi prilikom uklju&#x010D;enja u studiju podatci o pubertetskom razvoju dostupni su za njih &#x0161;est. Dvije su djevoj&#x010D;ice imale spontani pubertetski razvoj sa spontanom pojavom menarhe (33,3%, 2/6), dok su &#x010D;etiri razvile primarno zatajenje jajnika koje se o&#x010D;itovalo primarnom amenorejom (66,7% 4/6). Hormonsku nadomjesnu terapiju primale su sve djevojke sa zatajenjem jajnika.</p>
<p>Najranija denzitometrija ra&#x0111;ena je u &#x010D;etvrtoj godini &#x017E;ivota. Smanjena mineralna gusto&#x0107;a kostiju najranije je otkrivena u 12. godini &#x017E;ivota. Svi ispitanici sa smanjenom mineralnom gusto&#x0107;om kostiju imali su normalne koncentracije kalcija, fosfora i aktivnosti alkalne fosfataze u serumu. U na&#x0161;ih ispitanika podatci o patolo&#x0161;kim frakturama nisu zabilje&#x017E;eni.</p>
<p>Podatci o tjelesnoj masi i visini u tre&#x0107;oj i &#x010D;etvrtoj godini &#x017E;ivota bili su poznati za &#x0161;est djevoj&#x010D;ica i pet dje&#x010D;aka. Nitko od njih nije bilo tjelesne visine manje od 3. percentile za dob. Svi su imali uredan indeks tjelesne mase za dob.</p>
<p>Svi su se ispitanici koji su pre&#x017E;ivjeli po&#x010D;etne komplikacije bolesti i za koje su postojali podatci (n = 21) pridr&#x017E;avali bezmlije&#x010D;ne dijete. Nakon tre&#x0107;e godine &#x017E;ivota 42,9% (9/21) ispitanika primalo je dodatke prehrani, uklju&#x010D;uju&#x0107;i &#x017E;eljezo (9,5%, 2/21), kalcij (38,1%, 8/21) i vitamin D (28,6%, 6/21).</p>
<p>Medijan dobi pri zadnjoj kontroli za 91,3% (21/23) ispitanika bio je 7,6 godina s rasponom od dva mjeseca do 23,5 godine. Ve&#x0107;ina bolesnika (58,8%, 10/17) bila je hospitalizirana u KBC-u Zagreb samo jednom i kontrolirala se u Ambulanti za bolesti metabolizma Klinike za pedijatriju KBC-a Zagreb, u po&#x010D;etku svakih &#x0161;est mjeseci, a kasnije svakih godinu dana. Deset ispitanika mla&#x0111;ih od 18 godina nije bilo na kontroli dulje od dvije godine.</p>
<p>Studija je obuhvatila &#x010D;etiri para bra&#x0107;e i sestara. Medijan dobi pri zadnjoj kontroli prvoro&#x0111;enih s klasi&#x010D;nom galaktozemijom bio je 7 godina (7 mjeseci &#x2013; 23 godine), a drugoro&#x0111;enih s klasi&#x010D;nom galaktozemijom 5,5 godina (6 mjeseci &#x2013; 20 godina). Medijan dobi pri po&#x010D;etku terapije prvoro&#x0111;enih bio je 27,5 dana (10 &#x2013; 120 dana), a drugoro&#x0111;enih 0 dana (0 &#x2013; 53 dana). Svi prvoro&#x0111;eni imali su simptome u novoro&#x0111;ena&#x010D;kom razdoblju. Jedan bolesnik je umro u dobi od &#x0161;est tjedana. U skupini drugoro&#x0111;enih jedna je bolesnica, kojoj je dijagnoza postavljena u dobi od 53 dana, imala simptome u novoro&#x0111;ena&#x010D;kom razdoblju. Za jednu bolesnicu nije bilo podataka o simptomima u novoro&#x0111;ena&#x010D;koj dobi. Ostale dvije bolesnice u skupini drugoro&#x0111;enih bile su bez simptoma u novoro&#x0111;ena&#x010D;kom razdoblju i pri zadnjoj kontroli nisu zabilje&#x017E;ene dugoro&#x010D;ne komplikacije. U svih ostalih prvoro&#x0111;enih i drugoro&#x0111;enih razvila se barem jedna dugoro&#x010D;na komplikacija. Bra&#x0107;a i sestre preostalih dvaju bolesnika s pozitivnom obiteljskom anamnezom nisu uklju&#x010D;eni u ovu studiju. Za jednog bolesnika s pozitivnom obiteljskom anamnezom poznato je da je &#x010D;etvrto dijete roditelja koji su oboje heterozigotni nositelji mutacije gena <italic>GALT</italic>. Prethodno su imali dvije k&#x0107;eri. Jedna je umrla u dobi od tri i pol mjeseca, a druga u dobi od 15 dana. Taj bolesnik bio je bez simptoma u novoro&#x0111;ena&#x010D;kom razdoblju, ali su u njega kasnije zabilje&#x017E;ene dugoro&#x010D;ne komplikacije. Za drugu bolesnicu s pozitivnom obiteljskom anamnezom poznato je da je tre&#x0107;e dijete u obitelji. Prvi su bili blizanci koji su preminuli od galaktozemije u nepoznatoj dobi. Ta je bolesnica unato&#x010D; ranom po&#x010D;etku dijete imala simptome u novoro&#x0111;ena&#x010D;kom razdoblju, a kasnije je razvila brojne dugoro&#x010D;ne komplikacije.</p>
<p>Bolesnici s manjkom GALK-a u ovom prikazu su brat i sestra romskog podrijetla. Iz obiteljske anamneze izdvaja se da je k&#x0107;i bakinog brata slabovidna zbog katarakte. &#x017D;ensko dijete ro&#x0111;eno je iz trudno&#x0107;e komplicirane polihidramnijem. Po porodu je postavljena dijagnoza dijafragmalne hernije, zbog &#x010D;ega je i operirana. U dobi od 7,5 mjeseci, za vrijeme enteritisa, izmjerene su la&#x017E;no povi&#x0161;ene koncentracije glukoze iz kapilarne krvi glukometrom koji mo&#x017E;e dati la&#x017E;no povi&#x0161;en nalaz zbog interferencije s galaktozom. Tada je obradom ustanovljeno da djevoj&#x010D;ica ima visoku koncentraciju galaktoze u krvi i urinu nakon mlije&#x010D;nog obroka, a pregledom oka na&#x0161;lo se zamu&#x0107;enje le&#x0107;e u stra&#x017E;njem korteksu. Po postavljanju dijagnoze galaktozemije stavljena je na bezmlije&#x010D;nu dijetu. Naknadno su izmjereni normalna koncentracija galaktoza-1-fosfata i aktivnost GALT-a pa je postavljena dijagnoza manjka GALK-a. Kontrolni oftalmolo&#x0161;ki pregled u dobi od dvije godine pokazao je progresiju mrene te je u&#x010D;injena kapsulotomija oba oka. Na zadnjem kontrolnom pregledu u dobi od 4,5 godine bila je bez tegoba, psiholo&#x0161;ka procjena je ukazala na blago psihomotori&#x010D;ko zaostajanje, provodila se dijeta bez galaktoze uz dodatak kalcija i vitamina D. Mu&#x0161;ko dijete je od ro&#x0111;enja na dijeti bez galaktoze s obzirom na postavljenu dijagnozu u starije sestre. U dobi od dva tjedna u&#x010D;injen je test optere&#x0107;enja galaktozom kojim je potvr&#x0111;ena dijagnoza galaktozemije. Genskom analizom dokazano je da su oboje nositelji homozigotne mutacije c.82C&gt;A (p.P28T) gena <italic>GALK</italic>, koja je u&#x010D;estala u romskoj populaciji. Oba bolesnika izgubljena su iz daljnjeg pra&#x0107;enja.</p>
</sec>
<sec sec-type="other3">
<title>Rasprava</title>
<p>Klini&#x010D;ka slika klasi&#x010D;ne galaktozemije, kako po&#x010D;etna tako i u kasnijem tijeku, vrlo je raznolika i ovisi o rezidualnoj aktivnosti enzima, koja pak ovisi o vrsti mutacija gena <italic>GALT</italic> i njihovim brojnim kombinacijama. (<xref ref-type="bibr" rid="r36"><italic>36</italic></xref>) Zna&#x010D;ajna raznolikost biokemijskih i klini&#x010D;kih fenotipova mogu&#x0107;a je &#x010D;ak i unutar iste obitelji, odnosno u osoba s istim genotipom. U pregledu literature Varela-Leme i suradnika u&#x010D;estalost varijante Duarte bila je 2 &#x2013; 15% (<xref ref-type="bibr" rid="r37"><italic>37</italic></xref>), dok je u na&#x0161;ih bolesnika nije bilo, &#x0161;to se mo&#x017E;e objasniti nepostojanjem novoro&#x0111;ena&#x010D;kog probira u Hrvatskoj kojim se otkriva ova asimptomatska varijanta. Rezultati genske analize ve&#x0107;ine na&#x0161;ih ispitanika u &#x010D;lanku Petkovi&#x0107; Ramad&#x017E;e i suradnika pokazuju da je spektar mutacija klasi&#x010D;ne galaktozemije u Hrvatskoj ograni&#x010D;en na &#x010D;etiri mutacije, &#x0161;to bi se moglo iskoristiti za smi&#x0161;ljanje prikladne strategije brze molekularne dijagnostike u novoro&#x0111;en&#x010D;adi, osobito ako se uvede novoro&#x0111;ena&#x010D;ki probir na galaktozemiju. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>) Sve mutacije u na&#x0161;ih ispitanika otprije su opisane i povezane s te&#x0161;kom klini&#x010D;kom slikom. Dvije naj&#x010D;e&#x0161;&#x0107;e mutacije, c.563A&gt;G i c.855G&gt;T, udru&#x017E;ene su s potpunim gubitkom aktivnosti enzima GALT. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) Mutacija c.367C&gt;T jedina je besmislena mutacija i kao takva uzrokuje prerani prekid sinteze proteina i te&#x0161;ku klini&#x010D;ku sliku. (<xref ref-type="bibr" rid="r38"><italic>38</italic></xref>) Varijanta c.812G&gt;C opisana je dosad u samo jednog bolesnika i povezuje se s te&#x0161;kim manjkom enzima. (<xref ref-type="bibr" rid="r39"><italic>39</italic></xref>) Svi na&#x0161;i ispitanici za koje je genska osnova bila poznata imali su simptome u novoro&#x0111;ena&#x010D;kom razdoblju, osim jedne bolesnice s pozitivnom obiteljskom anamnezom. Svi na&#x0161;i ispitanici s istim genotipom nisu imali jednako razvijene dugoro&#x010D;ne komplikacije, ali se u obzir mora uzeti i dob pri zadnjoj kontroli. To bi moglo upu&#x0107;ivati da na razvoj komplikacija bolesti utje&#x010D;u i drugi &#x010D;imbenici osim genotipa, poput dobi pri po&#x010D;etku dijete i pridr&#x017E;avanje dijete, te da veza izme&#x0111;u genotipa i fenotipa nije u potpunosti jasna.</p>
<p>Rezultati mjerenja aktivnosti enzima GALT &#x010D;esto su, ovisno o kori&#x0161;tenim metodama, neprecizni. (<xref ref-type="bibr" rid="r31"><italic>31</italic></xref>) Zbog toga nerijetko slu&#x017E;e samo kao pomo&#x0107;no dijagnosti&#x010D;ko sredstvo za orijentaciju u postavljanju dijagnoze klasi&#x010D;ne galaktozemije. Primjer toga jest jedan na&#x0161; ispitanik &#x010D;ija je aktivnost enzima GALT bila skoro jednaka onoj u zdravoj populaciji (0,25 &#x00B5;kat/gHb naspram &gt;3 &#x00B5;kat/gHb).</p>
<p>Novoro&#x0111;ena&#x010D;ki probir omogu&#x0107;uje ranije postavljanje dijagnoze i raniji po&#x010D;etak dijete te posljedi&#x010D;no rje&#x0111;u pojavu simptoma. (<xref ref-type="bibr" rid="r40"><italic>40</italic></xref>) Tomu u prilog govori podatak da je u Estoniji, gdje se provodi novoro&#x0111;ena&#x010D;ki probir na klasi&#x010D;nu galaktozemiju, prosje&#x010D;na dob pri hospitalizaciji i pri potvrdi dijagnoze bila ranija nego u na&#x0161;ih ispitanika. (<xref ref-type="bibr" rid="r41"><italic>41</italic></xref>) Nadalje, u GalNet-ovoj studiji, koja je uklju&#x010D;ila i sedam na&#x0161;ih ispitanika, gotovo je polovica ispitanika bila otkrivena novoro&#x0111;ena&#x010D;kim probirom te je u njih bezmlije&#x010D;na dijeta zapo&#x010D;eta unutar prvog tjedna &#x017E;ivota, (<xref ref-type="bibr" rid="r42"><italic>42</italic></xref>) dok je na&#x0161;ih ispitanika bez pozitivne obiteljske anamneze u kojih je dijeta zapo&#x010D;eta u prvih sedam dana &#x017E;ivota bilo samo 11,1% (2/18). U skupini ameri&#x010D;kih bolesnika otkrivenih novoro&#x0111;ena&#x010D;kim probirom u&#x010D;estalost simptoma bila je oko 50%, (<xref ref-type="bibr" rid="r43"><italic>43</italic></xref>) &#x0161;to je manje nego u na&#x0161;ih ispitanika bez pozitivne obiteljske anamneze koji su u novoro&#x0111;ena&#x010D;kom razdoblju svi imali simptome. O ograni&#x010D;enoj koristi novoro&#x0111;ena&#x010D;kog probira govore studije u Ma&#x0111;arskoj i Italiji gdje je vi&#x0161;e od 90% novoro&#x0111;en&#x010D;adi bilo simptomatsko prije rezultata novoro&#x0111;ena&#x010D;kog probira, a &#x010D;ak njih 72,7% imalo je te&#x0161;ku klini&#x010D;ku sliku. (<xref ref-type="bibr" rid="r44"><italic>44</italic></xref>, <xref ref-type="bibr" rid="r45"><italic>45</italic></xref>)</p>
<p>Osim konjugirane &#x017E;utice, u sklopu klasi&#x010D;ne galaktozemije mo&#x017E;e se javiti i te&#x0161;ka novoro&#x0111;ena&#x010D;ka &#x017E;utica prete&#x017E;no nekonjugiranog tipa koja mo&#x017E;e dovesti do akutne bilirubinske encefalopatije i kernikterusa s dugoro&#x010D;nim komplikacijama. (<xref ref-type="bibr" rid="r46"><italic>46</italic></xref>) Patolo&#x0161;ku nekonjugiranu &#x017E;uticu s udjelom konjugiranog bilirubina manjim od 20% koncentracije ukupnog bilirubina imalo je 44,4% (4/9) na&#x0161;ih ispitanika. U jednog je bolesnika bila pripisana Rh-senzibilizaciji. Navedeno upu&#x0107;uje na potrebu uklju&#x010D;enja galaktozemije u diferencijalnu dijagnozu i nekonjugirane novoro&#x0111;ena&#x010D;ke &#x017E;utice.</p>
<p>Unato&#x010D; pridr&#x017E;avanju bezmlije&#x010D;ne dijete, 78,3% na&#x0161;ih bolesnika razvilo je barem jednu dugoro&#x010D;nu komplikaciju. U usporedbi izme&#x0111;u na&#x0161;e i drugih skupina javljaju se razli&#x010D;ite u&#x010D;estalosti, ali isti spektar komplikacija. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="r42"><italic>42</italic></xref>, <xref ref-type="bibr" rid="r43"><italic>43</italic></xref>) Razlike u u&#x010D;estalosti simptoma najvjerojatnije su posljedica postojanja novoro&#x0111;ena&#x010D;kog probira u nekim dr&#x017E;avama s posljedi&#x010D;no ranijim postavljanjem dijagnoze i po&#x010D;etkom dijete, ali i razlika u prosje&#x010D;noj dobi skupina ispitanika, pridr&#x017E;avanju dijete, razlika u genskoj podlozi i drugih jo&#x0161; nepoznatih &#x010D;imbenika.</p>
<p>Logopedske vje&#x017E;be poha&#x0111;alo je 70% na&#x0161;ih ispitanika s poreme&#x0107;ajem govora, &#x0161;to je usporedivo sa 65% u studiji Waggonera i suradnika. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>) Samo u jednoga na&#x0161;eg ispitanika postavljena je dijagnoza disartrije, a verbalne dispraksije nije bilo iako su kod nekih postojali elementi za tu dijagnozu. Tri od &#x010D;etiri na&#x0161;a ispitanika s poreme&#x0107;ajem govora koji su bili stariji od &#x0161;est godina i imali prosje&#x010D;ne intelektualne sposobnosti trebalo je neki oblik pomo&#x0107;i u nastavi ili imalo pote&#x0161;ko&#x0107;e s &#x010D;itanjem. &#x010C;e&#x0161;&#x0107;im procjenama od strane logopeda omogu&#x0107;ilo bi se pravodobno postavljanje to&#x010D;ne dijagnoze, logopedsko lije&#x010D;enje i ve&#x0107;a &#x0161;ansa za pobolj&#x0161;anjem govora, razvoja i obrazovnih postignu&#x0107;a.</p>
<p>Podatci o u&#x010D;estalosti poreme&#x0107;aja pona&#x0161;anja i psihi&#x010D;kih tegoba u bolesnika s klasi&#x010D;nom galaktozemijom opre&#x010D;ni su. Jedna studija navodi ve&#x0107;u u&#x010D;estalost anksioznosti u odrasloj populaciji bolesnika s klasi&#x010D;nom galaktozemijom u odnosu na zdravu populaciju. (<xref ref-type="bibr" rid="r47"><italic>47</italic></xref>) Druge studije nisu zabilje&#x017E;ile razliku u u&#x010D;estalosti psihi&#x010D;kih tegoba izme&#x0111;u bolesnika s klasi&#x010D;nom galaktozemijom i zdrave populacije. (<xref ref-type="bibr" rid="r42"><italic>42</italic></xref>, <xref ref-type="bibr" rid="r43"><italic>43</italic></xref>) U jednoga na&#x0161;eg bolesnika zabilje&#x017E;eni su elementi hiperaktivnosti s manjkom pa&#x017E;nje, u jednog anksioznost, a u njih troje poreme&#x0107;aji pa&#x017E;nje. Jedan na&#x0161; bolesnik trebao je psihijatrijsku skrb. Bolesnici s klasi&#x010D;nom galaktozemijom trebali bi se zbog prirode bolesti upu&#x0107;ivati psihologu na pregled i redovitu procjenu.</p>
<p>Na slikovnim prikazima mozga u osoba s klasi&#x010D;nom galaktozemijom mogu se vidjeti razli&#x010D;ite promjene. (<xref ref-type="bibr" rid="r48"><italic>48</italic></xref>) U na&#x0161;ih ispitanika, ne uklju&#x010D;uju&#x0107;i bolesnika koji je u novoro&#x0111;ena&#x010D;kom razdoblju prebolio meningitis, zabilje&#x017E;ene su leukoencefalopatija, zaka&#x0161;njela mijelinizacija, leukomalacija, pro&#x0161;ireni subarahnoidni prostor i difuzna atrofija mozga s pro&#x0161;irenim ventrikularnim sustavom. Svi ispitanici s promjenama na slikovnim pretragama mozga imali su neki razvojni poreme&#x0107;aj i/ili neurolo&#x0161;ku komplikaciju. Promjene bijele i sive tvari mozga mogu biti zna&#x010D;ajne za sporiju obradu informacija, memoriju, izvr&#x0161;no funkcioniranje, motoriku, govor i vi&#x0161;e kognitivne funkcije. (<xref ref-type="bibr" rid="r48"><italic>48</italic></xref>&#x2013;<xref ref-type="bibr" rid="r50"><italic>50</italic></xref>) Iako bi vrsta promjena u sredi&#x0161;njem &#x017E;iv&#x010D;anom sustavu mogla upu&#x0107;ivati na vrstu poreme&#x0107;aja i mo&#x017E;da omogu&#x0107;iti poduzimanje nekih preventivnih mjera, me&#x0111;unarodne smjernice za klasi&#x010D;nu galaktozemiju ne preporu&#x010D;uju rutinsku slikovnu dijagnostiku. (<xref ref-type="bibr" rid="r51"><italic>51</italic></xref>)</p>
<p>Galaktozemiju je va&#x017E;no na vrijeme prepoznati jer se na vrijeme zapo&#x010D;etom dijetom bez galaktoze nastanak katarakte mo&#x017E;e sprije&#x010D;iti, a ve&#x0107; postoje&#x0107;e katarakte mogu regredirati. Time se mo&#x017E;e smanjiti u&#x010D;estalost potrebe i komplikacija operacijskog lije&#x010D;enja katarakte. Nakon uvo&#x0111;enja dijete, katarakta iz novoro&#x0111;ena&#x010D;kog razdoblja nestala je u gotovo svih (4/5) na&#x0161;ih ispitanika, &#x0161;to je u skladu s podatcima iz literature. (<xref ref-type="bibr" rid="r42"><italic>42</italic></xref>) Katarakta nakon novoro&#x0111;ena&#x010D;kog razdoblja mogla bi biti posljedica nepridr&#x017E;avanja dijete. Protiv te hipoteze govori podatak da se katarakta nakon uvo&#x0111;enja dijete razvila u dva na&#x0161;a ispitanika koji su se navodno pridr&#x017E;avali dijete. U Waggonerovoj kohorti operirano je zbog katarakte ukupno osam bolesnika (8%) (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>), a u na&#x0161;oj jedan.</p>
<p>Zatajenje jajnika u klasi&#x010D;noj galaktozemiji posljedica je slo&#x017E;enih patogenetskih mehanizama koji uklju&#x010D;uju toksi&#x010D;no djelovanje galaktoze i njenih metabolita, poreme&#x0107;aje glikozilacije, signalnih puteva i ekspresije gena. Pokazalo se da su navedeni procesi neovisni o dijetetskom re&#x017E;imu tijekom &#x017E;ivota. Postoje pokazatelji da o&#x0161;te&#x0107;enje jajnika mo&#x017E;e zapo&#x010D;eti ve&#x0107; prenatalno. (<xref ref-type="bibr" rid="r52"><italic>52</italic></xref>) Navedeno rezultira poreme&#x0107;ajem funkcije jajnika, utje&#x010D;u&#x0107;i na procese folikulogeneze i sinteze spolnih hormona. (<xref ref-type="bibr" rid="r53"><italic>53</italic></xref>) Zatajenje jajnika razvija vi&#x0161;e od 90% bolesnica s klasi&#x010D;nom galaktozemijom, (<xref ref-type="bibr" rid="r52"><italic>52</italic></xref>) &#x0161;to je ne&#x0161;to vi&#x0161;e nego u na&#x0161;oj studiji (66,7%). Razlika je najvjerojatnije posljedica malog broja bolesnica generativne dobi i relativno kratkog pra&#x0107;enja u na&#x0161;em istra&#x017E;ivanju. Naime, dio bolesnica zatajenje jajnika razvija rano u dje&#x010D;joj dobi te u njih izostaje spontani pubertetski razvoj, no dio zatajenje jajnika razvija kasnije, nakon sponatnoga pubertetskog razvoja ili &#x010D;ak menarhe, pa te djevojke &#x010D;esto imaju smanjenu plodnost ili razvijaju preuranjenu menopauzu. U na&#x0161;ih bolesnica koje su razvile zatajenje jajnika koncentracije gonadotropina bile su povi&#x0161;ene i prije dobi o&#x010D;ekivanoga pubertetskog razvoja, u jedne bolesnice ve&#x0107; u dobi od osam godina, &#x0161;to je u skladu s postoje&#x0107;om literaturom. (<xref ref-type="bibr" rid="r54"><italic>54</italic></xref>) U na&#x0161;ih mu&#x0161;kih ispitanika nisu uo&#x010D;eni poreme&#x0107;aji spolnog ni pubertetskog razvoja, &#x0161;to je u skladu s dosada&#x0161;njim saznanjima o bolesti. (<xref ref-type="bibr" rid="r42"><italic>42</italic></xref>)</p>
<p>Pripravke kalcija i/ili vitamina D uzimali su svi na&#x0161;i bolesnici sa smanjenom mineralnom gusto&#x0107;om kostiju. U troje bolesnika s barem jednom kontrolnom denzitometrijom bilo je uo&#x010D;eno pobolj&#x0161;anje nakon suplementacije kalcijem i vitaminom D, od &#x010D;ega u dvoje samo djelomi&#x010D;no. Koncentracije kalcija i fosfora i aktivnost alkalne fosfataze bile su normalne u gotovo svih na&#x0161;ih ispitanika sa smanjenom mineralnom gusto&#x0107;om kostiju, &#x0161;to je u skladu s literaturom. (<xref ref-type="bibr" rid="r55"><italic>55</italic></xref>) Koncentracija 25-OH-D3 izmjerena je samo u jednoga na&#x0161;eg bolesnika, &#x0161;to je sli&#x010D;no literaturnim podatcima koji govore o rijetkom mjerenju 25-OH-D3 u bolesnika s galaktozemijom (<xref ref-type="bibr" rid="r56"><italic>56</italic></xref>), iako smjernice nagla&#x0161;avaju potrebu navedenog (<xref ref-type="bibr" rid="r51"><italic>51</italic></xref>). Me&#x0111;unarodne smjernice za klasi&#x010D;nu galaktozemiju preporu&#x010D;uju probir za smanjenu mineralnu gusto&#x0107;u kostiju u dobi od osam do deset godina. (<xref ref-type="bibr" rid="r51"><italic>51</italic></xref>) Medijan dobi u na&#x0161;ih ispitanika pri prvoj denzitometriji bio je u 14. godini s rasponom od &#x010D;etvrte do 23. godine, &#x0161;to sugerira da se procjena mineralne gusto&#x0107;e kostiju u nekih radi prekasno.</p>
<p>U ve&#x0107;ine na&#x0161;ih ispitanika smanjena tjelesna masa i tjelesna duljina/visina zabilje&#x017E;ene su unutar dojena&#x010D;kog razdoblja, po svemu uslijed klini&#x010D;kog o&#x010D;itovanja bolesti u novoro&#x0111;ena&#x010D;kom razdoblju. Kasnije se uo&#x010D;ava ubrzan prirast tjelesne mase i duljine/visine. U ispitanika iz studije Waggonera i suradnika rast je bio zna&#x010D;ajno usporen tijekom djetinjstva i ranog puberteta, a pobolj&#x0161;ao se tek u kasnom pubertetu uz normalnu kona&#x010D;nu visinu. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>)</p>
<p>Razumljivo je da spoznaja o klasi&#x010D;noj galaktozemiji u bra&#x0107;e ili sestara omogu&#x0107;uje zna&#x010D;ajno ubrzanje postavljanja dijagnoze i izbjegavanje lo&#x0161;eg ishoda u novoro&#x0111;ena&#x010D;kom razdoblju, osobito u zemljama kao &#x0161;to je Hrvatska u kojima klasi&#x010D;na galaktozemija nije uklju&#x010D;ena u program novoro&#x0111;ena&#x010D;kog probira. Zato je i u na&#x0161;ih ispitanika u&#x010D;estalost simptoma u novoro&#x0111;ena&#x010D;kom razdoblju bila manja u drugoro&#x0111;enih s klasi&#x010D;nom galaktozemijom nego u prvoro&#x0111;enih. Usporedba prvoro&#x0111;enih i drugoro&#x0111;enih s klasi&#x010D;nom galaktozemijom iz iste obitelji otvara mogu&#x0107;nost da se prepoznaju &#x010D;imbenici koji mimo genotipa utje&#x010D;u na dugoro&#x010D;ni tijek bolesti. Iako je mali broj parova ispitanika iz istih obitelji, &#x010D;ini se da redoslijed ro&#x0111;enja nije toliko utjecao na razvoj dugoro&#x010D;nih komplikacija jer su se one pojavile u objema skupinama. To je u skladu s rezultatima Waggonerove studije prema kojima nije bilo statisti&#x010D;ki zna&#x010D;ajne razlike u kvocijentu inteligencije, u&#x010D;estalosti poreme&#x0107;aja govora i funkcije jajnika me&#x0111;u prvoro&#x0111;enima i drugoro&#x0111;enima s klasi&#x010D;nom galaktozemijom, &#x0161;to tako&#x0111;er govori da tijek i ishod u novoro&#x0111;ena&#x010D;koj dobi ne odre&#x0111;uju ili barem ne odre&#x0111;uju potpuno dugoro&#x010D;ni tijek bolesti. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>)</p>
<p>Iako je na&#x0161;a studija obuhvatila ve&#x0107;inu bolesnika s klasi&#x010D;nom galaktozemijom u Hrvatskoj, ona ima odre&#x0111;ena ograni&#x010D;enja. Rije&#x010D; je o razmjerno malom broju ispitanika koji su obra&#x0111;eni retrospektivno. Svi bolesnici nisu bili pra&#x0107;eni na isti standardizirani na&#x010D;in, &#x0161;to ote&#x017E;ava uniformno obra&#x0111;ivanje i uspore&#x0111;ivanje podataka. Neki su podatci bili nedostupni. Ve&#x0107;ina ispitanika nakon punoljetnosti, a neki i ranije, prestali su s pra&#x0107;enjem kod pedijatra &#x010D;ime je ote&#x017E;ano longitudinalno pra&#x0107;enje, osobito dugoro&#x010D;nih komplikacija.</p>
</sec>
<sec sec-type="other4">
<title>Zaklju&#x010D;ak</title>
<p>Na&#x0161;a studija pokazuje da u Hrvatskoj velika ve&#x0107;ina djece s klasi&#x010D;nom galaktozemijom prebrodi jetrenu bolest u novoro&#x0111;ena&#x010D;kom razdoblju, iako se dijagnoza &#x010D;esto postavlja dosta kasno. Zbog toga je, osobito u okolnostima dok u Hrvatskoj nema novoro&#x0111;ena&#x010D;kog probira na galaktozemiju, nu&#x017E;no pove&#x0107;ati svijest o galaktozemiji u svih pedijatara, poglavito neonatologa. Dugoro&#x010D;ne, patogenetski jo&#x0161; nerazja&#x0161;njene komplikacije &#x010D;este su kao i u drugim populacijama. Daljnja istra&#x017E;ivanja, osobito prospektivnog tipa s ve&#x0107;im uzorkom, potrebna su kako bi se rasvijetlila slo&#x017E;ena patogeneza ove bolesti, definirala va&#x017E;nost pojedinih prediktivnih &#x010D;imbenika za razvoj dugoro&#x010D;nih komplikacija te omogu&#x0107;ila primjerena intervencija za dobrobit bolesnika.</p>
</sec>
</body>
<back>
<ack>
<title>ZAHVALA</title>
<p>Autori zahvaljuju svim bolesnicima i njihovim roditeljima koji su pridonijeli ovom istra&#x017E;ivanju i svim kolegama i drugom zdravstvenom osoblju koji su sudjelovali u skrbi o ovim bolesnicima. Danijela Petkovi&#x0107; Ramad&#x017E;a, Tamara &#x017D;igman, Ksenija Fumi&#x0107; i Ivo Bari&#x0107; &#x010D;lanovi su Europske mre&#x017E;e referentnih centara za rijetke nasljedne metaboli&#x010D;ke bolesti (European Reference Network for Rare Hereditary Metabolic Disorders -MetabERN &#x2014;Project ID #739543). Jurica Vukovi&#x0107; &#x010D;lan je Europske mre&#x017E;e referentnih centara za rijetke bolesti jetre (ERN Rare Liver).</p>
</ack>
<fn-group>
<fn fn-type="conflict">
<p content-type="fn-title">INFORMACIJA O SUKOBU INTERESA</p>
<p>Autori nisu deklarirali sukob interesa relevantan za ovaj rad.</p>
</fn>
<fn fn-type="financial-disclosure">
<p content-type="fn-title">INFORMACIJA O FINANCIRANJU</p>
<p>Za ovaj &#x010D;lanak nisu primljena financijska sredstva.</p>
</fn>
</fn-group>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="book">Segal SBG. Disorders of Galactose Metabolism. U: Scriver C, Beaudet A, Sly W, Valle D, ur. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill Professional; 2001, str. 1553&#x2013;89.</mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>Y</given-names></name><name><surname>Kikuchi</surname><given-names>A</given-names></name><name><surname>Arai-Ichinoi</surname><given-names>N</given-names></name><name><surname>Sakamoto</surname><given-names>O</given-names></name><name><surname>Takezawa</surname><given-names>Y</given-names></name><name><surname>Iwasawa</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Biallelic GALM pathogenic variants cause a novel type of galactosemia.</article-title> <source>Genet Med</source>. <year>2020</year>;<volume>22</volume>:<fpage>1281</fpage>. <pub-id pub-id-type="doi">10.1038/s41436-020-0836-z</pub-id><pub-id pub-id-type="pmid">32499603</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>M</given-names></name><name><surname>Mchugh</surname><given-names>B</given-names></name><name><surname>Tighe</surname><given-names>O</given-names></name><name><surname>Mayne</surname><given-names>P</given-names></name><name><surname>O&#x2019;Neill</surname><given-names>C</given-names></name><name><surname>Naughten</surname><given-names>E</given-names></name><etal/></person-group> <article-title>Genetic basis of transferase-deficient galactosaemia in Ireland and the population history of the Irish Travellers.</article-title> <source>Eur J Hum Genet</source>. <year>1999</year>;<volume>7</volume>:<fpage>549</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejhg.5200327</pub-id><pub-id pub-id-type="pmid">10439960</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirokawa</surname><given-names>H</given-names></name><name><surname>Okano</surname><given-names>Y</given-names></name><name><surname>Asada</surname><given-names>M</given-names></name><name><surname>Fujimoto</surname><given-names>A</given-names></name><name><surname>Suyama</surname><given-names>I</given-names></name><name><surname>Isshiki</surname><given-names>G</given-names></name></person-group>. <article-title>Molecular basis for phenotypic heterogeneity in galactosaemia: prediction of clinical phenotype from genotype in Japanese patients.</article-title> <source>Eur J Hum Genet</source>. <year>1999</year>;<volume>7</volume>:<fpage>757</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejhg.5200368</pub-id><pub-id pub-id-type="pmid">10573007</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="other">Berry GT. Classic galactosemia and clinical variant galactosemia. U: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., ur. GeneReviews&#x00AE; [Internet]. Seattle (WA): University of Washington; 1993&#x2013;2022.</mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinelli</surname><given-names>D</given-names></name><name><surname>Bernardi</surname><given-names>B</given-names></name><name><surname>Napolitano</surname><given-names>A</given-names></name><name><surname>Colafati</surname><given-names>GS</given-names></name><name><surname>Dionisi-Vici</surname><given-names>C</given-names></name></person-group>. <article-title>Teaching neuroImages: Galactitol peak and fatal cerebral edema in classic galactosemia: Too much sugar in the brain.</article-title> <source>Neurology</source>. <year>2016</year>;<volume>86</volume>:<fpage>e32</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000002284</pub-id><pub-id pub-id-type="pmid">26783274</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schadewaldt</surname><given-names>P</given-names></name><name><surname>Kamalanathan</surname><given-names>L</given-names></name><name><surname>Hammen</surname><given-names>HW</given-names></name><name><surname>Wendel</surname><given-names>U</given-names></name></person-group>. <article-title>Age dependence of endogenous galactose formation in Q188R homozygous galactosemic patients.</article-title> <source>Mol Genet Metab</source>. <year>2004</year>;<volume>81</volume>:<fpage>31</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2003.10.007</pub-id><pub-id pub-id-type="pmid">14728989</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waggoner</surname><given-names>DD</given-names></name><name><surname>Buist</surname><given-names>NRM</given-names></name><name><surname>Donnell</surname><given-names>GN</given-names></name></person-group>. <article-title>Long-term prognosis in galactosaemia: Results of a survey of 350 cases.</article-title> <source>J Inherit Metab Dis</source>. <year>1990</year>;<volume>13</volume>:<fpage>802</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1007/BF01800204</pub-id><pub-id pub-id-type="pmid">1706789</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coss</surname><given-names>KP</given-names></name><name><surname>Byrne</surname><given-names>JC</given-names></name><name><surname>Coman</surname><given-names>DJ</given-names></name><name><surname>Adamczyk</surname><given-names>B</given-names></name><name><surname>Abrahams</surname><given-names>JL</given-names></name><name><surname>Saldova</surname><given-names>R</given-names></name><etal/></person-group> <article-title>IgG N-glycans as potential biomarkers for determining galactose tolerance in classical galactosaemia.</article-title> <source>Mol Genet Metab</source>. <year>2012</year>;<volume>105</volume>:<fpage>212</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2011.10.018</pub-id><pub-id pub-id-type="pmid">22133299</pub-id></mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knerr</surname><given-names>I</given-names></name><name><surname>Coss</surname><given-names>KP</given-names></name><name><surname>Kratzsch</surname><given-names>J</given-names></name><name><surname>Crushell</surname><given-names>E</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Doran</surname><given-names>P</given-names></name><etal/></person-group> <article-title>Effects of temporary low-dose galactose supplements in children aged 5-12 y with classical galactosemia: A pilot study.</article-title> <source>Pediatr Res</source>. <year>2015</year>;<volume>78</volume>:<fpage>272</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/pr.2015.107</pub-id><pub-id pub-id-type="pmid">26053138</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Odejinmi</surname><given-names>SI</given-names></name><name><surname>Vankayalapati</surname><given-names>H</given-names></name><name><surname>Wierenga</surname><given-names>KJ</given-names></name><name><surname>Lai</surname><given-names>K</given-names></name></person-group>. <article-title>Innovative therapy for classic galactosemia &#x2013; Tale of two HTS.</article-title> <source>Mol Genet Metab</source>. <year>2012</year>;<volume>105</volume>:<fpage>44</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2011.09.028</pub-id><pub-id pub-id-type="pmid">22018723</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumbo-Lucioni</surname><given-names>PP</given-names></name><name><surname>Ryan</surname><given-names>EL</given-names></name><name><surname>Hopson</surname><given-names>ML</given-names></name><name><surname>Bishop</surname><given-names>HM</given-names></name><name><surname>Weitner</surname><given-names>T</given-names></name><name><surname>Tovmasyan</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Manganese-based superoxide dismutase mimics modify both acute and long-term outcome severity in a Drosophila melanogaster model of classic galactosemia.</article-title> <source>Antioxid Redox Signal</source>. <year>2014</year>;<volume>20</volume>:<fpage>2361</fpage>&#x2013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2012.5122</pub-id><pub-id pub-id-type="pmid">23758052</pub-id></mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelho</surname><given-names>AI</given-names></name><name><surname>Trabuco</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>R</given-names></name><name><surname>Silva</surname><given-names>MJ</given-names></name><name><surname>Tavares de Almeida</surname><given-names>I</given-names></name><name><surname>Leandro</surname><given-names>P</given-names></name><etal/></person-group> <article-title>Functional and structural impact of the most prevalent missense mutations in classic galactosemia.</article-title> <source>Mol Genet Genomic Med</source>. <year>2014</year>;<volume>2</volume>:<fpage>484</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1002/mgg3.94</pub-id><pub-id pub-id-type="pmid">25614870</pub-id></mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balakrishnan</surname><given-names>B</given-names></name><name><surname>An</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>V</given-names></name><name><surname>DeAntonis</surname><given-names>C</given-names></name><name><surname>Martini</surname><given-names>PGV</given-names></name><name><surname>Lai</surname><given-names>K</given-names></name></person-group>. <article-title>Novel mRNA-based therapy reduces toxic galactose metabolites and overcomes galactose sensitivity in a mouse model of classic galactosemia.</article-title> <source>Mol Ther</source>. <year>2020</year>;<volume>28</volume>:<fpage>304</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2019.09.018</pub-id><pub-id pub-id-type="pmid">31604675</pub-id></mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelho</surname><given-names>AI</given-names></name><name><surname>Louren&#x00E7;o</surname><given-names>S</given-names></name><name><surname>Trabuco</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>MJ</given-names></name><name><surname>Oliveira</surname><given-names>A</given-names></name><name><surname>Gaspar</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Functional correction by antisense therapy of a splicing mutation in the GALT gene.</article-title> <source>Eur J Hum Genet</source>. <year>2015</year>;<volume>23</volume>:<fpage>500</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2014.149</pub-id><pub-id pub-id-type="pmid">25052314</pub-id></mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carney</surname><given-names>AE</given-names></name><name><surname>Sanders</surname><given-names>RD</given-names></name><name><surname>Garza</surname><given-names>KR</given-names></name><name><surname>McGaha</surname><given-names>LA</given-names></name><name><surname>Bean</surname><given-names>LJH</given-names></name><name><surname>Coffee</surname><given-names>BW</given-names></name><etal/></person-group> <article-title>Origins, distribution and expression of the Duarte-2 (D2) allele of galactose-1-phosphate uridylyltransferase.</article-title> <source>Hum Mol Genet</source>. <year>2009</year>;<volume>18</volume>:<fpage>1624</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddp080</pub-id><pub-id pub-id-type="pmid">19224951</pub-id></mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsas</surname><given-names>LJ</given-names></name><name><surname>Lai</surname><given-names>K</given-names></name><name><surname>Saunders</surname><given-names>CJ</given-names></name><name><surname>Langley</surname><given-names>SD</given-names></name></person-group>. <article-title>Functional analysis of the human galactose-1-phosphate uridyltransferase promoter in Duarte and LA variant galactosemia.</article-title> <source>Mol Genet Metab</source>. <year>2001</year>;<volume>72</volume>:<fpage>297</fpage>&#x2013;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1006/mgme.2001.3157</pub-id><pub-id pub-id-type="pmid">11286503</pub-id></mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="other">Fridovich-Keil JL, Gambello MJ, Singh RH, Sharer JD. Duarte variant galactosemia. U: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K i sur, ur. GeneReviews&#x00AE; [Internet]. Seattle: University of Washington; 1993&#x2013;2022.</mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ficicioglu</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>N</given-names></name><name><surname>Yager</surname><given-names>C</given-names></name><name><surname>Gallagher</surname><given-names>PR</given-names></name><name><surname>Hussa</surname><given-names>C</given-names></name><name><surname>Mattie</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Duarte (DG) galactosemia: A pilot study of biochemical and neurodevelopmental assessment in children detected by newborn screening.</article-title> <source>Mol Genet Metab</source>. <year>2008</year>;<volume>95</volume>:<fpage>206</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2008.09.005</pub-id><pub-id pub-id-type="pmid">18976948</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlock</surname><given-names>G</given-names></name><name><surname>Fischer</surname><given-names>ST</given-names></name><name><surname>Lynch</surname><given-names>ME</given-names></name><name><surname>Potter</surname><given-names>NL</given-names></name><name><surname>Coles</surname><given-names>CD</given-names></name><name><surname>Epstein</surname><given-names>MP</given-names></name><etal/></person-group> <article-title>Developmental outcomes in Duarte galactosemia.</article-title> <source>Pediatrics</source>. <year>2019</year>;<volume>143</volume>:<elocation-id>20182516</elocation-id>. <pub-id pub-id-type="doi">10.1542/peds.2018-2516</pub-id><pub-id pub-id-type="pmid">30593450</pub-id></mixed-citation></ref>
<ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stroek</surname><given-names>K</given-names></name><name><surname>Bouva</surname><given-names>MJ</given-names></name><name><surname>Schielen</surname><given-names>PCJI</given-names></name><name><surname>Vaz</surname><given-names>FM</given-names></name><name><surname>Heijboer</surname><given-names>AC</given-names></name><name><surname>de Jonge</surname><given-names>R</given-names></name><etal/></person-group> <article-title>Recommendations for newborn screening for galactokinase deficiency: A systematic review and evaluation of Dutch newborn screening data.</article-title> <source>Mol Genet Metab</source>. <year>2018</year>;<volume>124</volume>:<fpage>50</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2018.03.008</pub-id><pub-id pub-id-type="pmid">29580649</pub-id></mixed-citation></ref>
<ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>AM</given-names></name><name><surname>Bakker</surname><given-names>HD</given-names></name><name><surname>van Gennip</surname><given-names>AH</given-names></name></person-group>. <article-title>van Kempen J v., Wanders RJA, Wijburg FA. Clinical features of galactokinase deficiency: A review of the literature.</article-title> <source>J Inherit Metab Dis</source>. <year>2002</year>;<volume>25</volume>:<fpage>629</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1023/A:1022875629436</pub-id><pub-id pub-id-type="pmid">12705493</pub-id></mixed-citation></ref>
<ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennermann</surname><given-names>JB</given-names></name><name><surname>Schadewaldt</surname><given-names>P</given-names></name><name><surname>Vetter</surname><given-names>B</given-names></name><name><surname>Shin</surname><given-names>YS</given-names></name><name><surname>M&#x00F6;nch</surname><given-names>E</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name></person-group>. <article-title>Features and outcome of galactokinase deficiency in children diagnosed by newborn screening.</article-title> <source>J Inherit Metab Dis</source>. <year>2011</year>;<volume>34</volume>:<fpage>399</fpage>&#x2013;<lpage>407</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-010-9270-8</pub-id><pub-id pub-id-type="pmid">21290184</pub-id></mixed-citation></ref>
<ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubio-Gozalbo</surname><given-names>ME</given-names></name><name><surname>Derks</surname><given-names>B</given-names></name><name><surname>Das</surname><given-names>AM</given-names></name><name><surname>Meyer</surname><given-names>U</given-names></name><name><surname>M&#x00F6;slinger</surname><given-names>D</given-names></name><name><surname>Couce</surname><given-names>ML</given-names></name><etal/></person-group> <article-title>Galactokinase deficiency: lessons from the GalNet registry.</article-title> <source>Genet Med</source>. <year>2021</year>;<volume>23</volume>:<fpage>202</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1038/s41436-020-00942-9</pub-id><pub-id pub-id-type="pmid">32807972</pub-id></mixed-citation></ref>
<ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Openo</surname><given-names>KK</given-names></name><name><surname>Schulz</surname><given-names>JM</given-names></name><name><surname>Vargas</surname><given-names>CA</given-names></name><name><surname>Orton</surname><given-names>CS</given-names></name><name><surname>Epstein</surname><given-names>MP</given-names></name><name><surname>Schnur</surname><given-names>RE</given-names></name><etal/></person-group> <article-title>Epimerase-deficiency galactosemia is not a binary condition.</article-title> <source>Am J Hum Genet</source>. <year>2006</year>;<volume>78</volume>:<fpage>89</fpage>&#x2013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1086/498985</pub-id><pub-id pub-id-type="pmid">16385452</pub-id></mixed-citation></ref>
<ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias Costa</surname><given-names>F</given-names></name><name><surname>Ferdinandusse</surname><given-names>S</given-names></name><name><surname>Pinto</surname><given-names>C</given-names></name><name><surname>Dias</surname><given-names>A</given-names></name><name><surname>Keldermans</surname><given-names>L</given-names></name><name><surname>Quelhas</surname><given-names>D</given-names></name><etal/></person-group> <article-title>Galactose epimerase deficiency: Expanding the phenotype.</article-title> <source>JIMD.</source> <year>2017</year>;<volume>37</volume>:<fpage>19</fpage>&#x2013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">28247339</pub-id></mixed-citation></ref>
<ref id="r27"><label>27</label><mixed-citation publication-type="other">Fridovich-Keil J, Bean L, He M, Schroer R. Epimerase deficiency galactosemia. U: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K i sur, ur. GeneReviews&#x00AE; [Internet]. Seattle: University of Washington; 1993&#x2013;2022.</mixed-citation></ref>
<ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasawa</surname><given-names>S</given-names></name><name><surname>Kikuchi</surname><given-names>A</given-names></name><name><surname>Wada</surname><given-names>Y</given-names></name><name><surname>Arai-Ichinoi</surname><given-names>N</given-names></name><name><surname>Sakamoto</surname><given-names>O</given-names></name><name><surname>Tamiya</surname><given-names>G</given-names></name><etal/></person-group> <article-title>The prevalence of GALM mutations that cause galactosemia: A database of functionally evaluated variants.</article-title> <source>Mol Genet Metab</source>. <year>2019</year>;<volume>126</volume>:<fpage>362</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2019.01.018</pub-id><pub-id pub-id-type="pmid">30910422</pub-id></mixed-citation></ref>
<ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kono</surname><given-names>T</given-names></name><name><surname>Hiki</surname><given-names>T</given-names></name><name><surname>Kuwashima</surname><given-names>S</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Kaji</surname><given-names>Y</given-names></name></person-group>. <article-title>Hypergalactosemia in early infancy: Diagnostic strategy with an emphasis on imaging.</article-title> <source>Pediatr Int</source>. <year>2009</year>;<volume>51</volume>:<fpage>276</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1111/j.1442-200X.2008.02692.x</pub-id><pub-id pub-id-type="pmid">19405932</pub-id></mixed-citation></ref>
<ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>Y</given-names></name><name><surname>Tajima</surname><given-names>G</given-names></name><name><surname>Bahagia</surname><given-names>AD</given-names></name><name><surname>Sakamoto</surname><given-names>A</given-names></name><name><surname>Ono</surname><given-names>H</given-names></name><name><surname>Sakura</surname><given-names>N</given-names></name><etal/></person-group> <article-title>Differential diagnosis of neonatal mild hypergalactosaemia detected by mass screening: Clinical significance of portal vein imaging.</article-title> <source>J Inherit Metab Dis</source>. <year>2004</year>;<volume>27</volume>:<fpage>11</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1023/B:BOLI.0000016621.29854.d6</pub-id><pub-id pub-id-type="pmid">14970742</pub-id></mixed-citation></ref>
<ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquali</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Coffee</surname><given-names>B</given-names></name></person-group>. <article-title>Laboratory diagnosis of galactosemia: a technical standard and guideline of the American College of Medical Genetics and Genomics.</article-title> <source>Genet Med</source>. <year>2018</year>;<volume>20</volume>:<fpage>3</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2017.172</pub-id><pub-id pub-id-type="pmid">29261178</pub-id></mixed-citation></ref>
<ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotb</surname><given-names>MA</given-names></name><name><surname>Mansour</surname><given-names>L</given-names></name><name><surname>Shamma</surname><given-names>RA</given-names></name></person-group>. <article-title>Screening for galactosemia: Is there a place for it?</article-title> <source>Int J Gen Med</source>. <year>2019</year>;<volume>12</volume>:<fpage>193</fpage>&#x2013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.2147/IJGM.S180706</pub-id><pub-id pub-id-type="pmid">31213878</pub-id></mixed-citation></ref>
<ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squires</surname><given-names>RH</given-names></name><name><surname>Shneider</surname><given-names>BL</given-names></name><name><surname>Bucuvalas</surname><given-names>J</given-names></name><name><surname>Alonso</surname><given-names>E</given-names></name><name><surname>Sokol</surname><given-names>RJ</given-names></name><name><surname>Narkewicz</surname><given-names>MR</given-names></name><etal/></person-group> <article-title>Acute liver failure in children: The first 348 patients in the pediatric acute liver failure study group.</article-title> <source>J Pediatr</source>. <year>2006</year>;<volume>148</volume>:<fpage>652</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2005.12.051</pub-id><pub-id pub-id-type="pmid">16737880</pub-id></mixed-citation></ref>
<ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baim</surname><given-names>S</given-names></name><name><surname>Leonard</surname><given-names>MB</given-names></name><name><surname>Bianchi</surname><given-names>ML</given-names></name><name><surname>Hans</surname><given-names>DB</given-names></name><name><surname>Kalkwarf</surname><given-names>HJ</given-names></name><name><surname>Langman</surname><given-names>CB</given-names></name><etal/></person-group> <article-title>Official positions of the international society for clinical densitometry and executive summary of the 2007 ISCD Pediatric position development conference.</article-title> <source>J Clin Densitom</source>. <year>2008</year>;<volume>11</volume>:<fpage>6</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jocd.2007.12.002</pub-id><pub-id pub-id-type="pmid">18442749</pub-id></mixed-citation></ref>
<ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramad&#x017E;a</surname><given-names>DP</given-names></name><name><surname>Sarnavka</surname><given-names>V</given-names></name><name><surname>Vukovi&#x0107;</surname><given-names>J</given-names></name><name><surname>Fumi&#x0107;</surname><given-names>K</given-names></name><name><surname>Kr&#x017E;elj</surname><given-names>V</given-names></name><name><surname>Lozi&#x0107;</surname><given-names>B</given-names></name><etal/></person-group> <article-title>Molecular basis and clinical presentation of classic galactosemia in a Croatian population.</article-title> <source>J Pediatr Endocrinol Metab</source>. <year>2018</year>;<volume>31</volume>:<fpage>71</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1515/jpem-2017-0302</pub-id><pub-id pub-id-type="pmid">29252199</pub-id></mixed-citation></ref>
<ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riehman</surname><given-names>K</given-names></name><name><surname>Crews</surname><given-names>C</given-names></name><name><surname>Fridovich-Keil</surname><given-names>JL</given-names></name></person-group>. <article-title>Relationship between genotype, activity, and galactose sensitivity in yeast expressing patient alleles of human galactose-1-phosphate uridylyltransferase.</article-title> <source>J Biol Chem</source>. <year>2001</year>;<volume>276</volume>:<fpage>10634</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M009583200</pub-id><pub-id pub-id-type="pmid">11152465</pub-id></mixed-citation></ref>
<ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varela-Lema</surname><given-names>L</given-names></name><name><surname>Paz-Valinas</surname><given-names>L</given-names></name><name><surname>Atienza-Merino</surname><given-names>G</given-names></name><name><surname>Zubizarreta-Alberdi</surname><given-names>R</given-names></name><name><surname>Villares</surname><given-names>RV</given-names></name><name><surname>L&#x00F3;pez-Garc&#x00ED;a</surname><given-names>M</given-names></name></person-group>. <article-title>Appropriateness of newborn screening for classic galactosaemia: a systematic review.</article-title> <source>J Inherit Metab Dis</source>. <year>2016</year>;<volume>39</volume>:<fpage>633</fpage>&#x2013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-016-9936-y</pub-id><pub-id pub-id-type="pmid">27116003</pub-id></mixed-citation></ref>
<ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boutron</surname><given-names>A</given-names></name><name><surname>Marabotti</surname><given-names>A</given-names></name><name><surname>Facchiano</surname><given-names>A</given-names></name><name><surname>Cheillan</surname><given-names>D</given-names></name><name><surname>Zater</surname><given-names>M</given-names></name><name><surname>Oliveira</surname><given-names>C</given-names></name><etal/></person-group> <article-title>Mutation spectrum in the French cohort of galactosemic patients and structural simulation of 27 novel missense variations.</article-title> <source>Mol Genet Metab</source>. <year>2012</year>;<volume>107</volume>:<fpage>438</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2012.07.025</pub-id><pub-id pub-id-type="pmid">22944367</pub-id></mixed-citation></ref>
<ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calderon</surname><given-names>FRO</given-names></name><name><surname>Phansalkar</surname><given-names>AR</given-names></name><name><surname>Crockett</surname><given-names>DK</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Mao</surname><given-names>R</given-names></name></person-group>. <article-title>Mutation database for the galactose-1-phosphate uridyltransferase (GALT) gene.</article-title> <source>Hum Mutat</source>. <year>2007</year>;<volume>28</volume>:<fpage>939</fpage>&#x2013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1002/humu.20544</pub-id><pub-id pub-id-type="pmid">17486650</pub-id></mixed-citation></ref>
<ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porta</surname><given-names>F</given-names></name><name><surname>Pagliardini</surname><given-names>S</given-names></name><name><surname>Pagliardini</surname><given-names>V</given-names></name><name><surname>Ponzone</surname><given-names>A</given-names></name><name><surname>Spada</surname><given-names>M</given-names></name></person-group>. <article-title>Newborn screening for galactosemia: a 30-year single center experience.</article-title> <source>World J Pediatr</source>. <year>2015</year>;<volume>11</volume>:<fpage>160</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1007/s12519-015-0017-3</pub-id><pub-id pub-id-type="pmid">25754754</pub-id></mixed-citation></ref>
<ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00D5;unap</surname><given-names>K</given-names></name><name><surname>Joost</surname><given-names>K</given-names></name><name><surname>Temberg</surname><given-names>T</given-names></name><name><surname>Krabbi</surname><given-names>K</given-names></name><name><surname>T&#x00F5;nisson</surname><given-names>N</given-names></name></person-group>. <article-title>Classical galactosemia in Estonia: selective neonatal screening, incidence, and genotype/phenotype data of diagnosed patients.</article-title> <source>J Inherit Metab Dis</source>. <year>2010</year>;<volume>33</volume>:<fpage>175</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-010-9045-2</pub-id><pub-id pub-id-type="pmid">20151200</pub-id></mixed-citation></ref>
<ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubio-Gozalbo</surname><given-names>ME</given-names></name><name><surname>Haskovic</surname><given-names>M</given-names></name><name><surname>Bosch</surname><given-names>AM</given-names></name><name><surname>Burnyte</surname><given-names>B</given-names></name><name><surname>Coelho</surname><given-names>AI</given-names></name><name><surname>Cassiman</surname><given-names>D</given-names></name><etal/></person-group> <article-title>The natural history of classic galactosemia: Lessons from the GalNet registry.</article-title> <source>Orphanet J Rare Dis</source>. <year>2019</year>;<volume>14</volume>:<fpage>86</fpage>. <pub-id pub-id-type="doi">10.1186/s13023-019-1047-z</pub-id><pub-id pub-id-type="pmid">31029175</pub-id></mixed-citation></ref>
<ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuzyuk</surname><given-names>T</given-names></name><name><surname>Viau</surname><given-names>K</given-names></name><name><surname>Andrews</surname><given-names>A</given-names></name><name><surname>Pasquali</surname><given-names>M</given-names></name><name><surname>Longo</surname><given-names>N</given-names></name></person-group>. <article-title>Biochemical changes and clinical outcomes in 34 patients with classic galactosemia.</article-title> <source>J Inherit Metab Dis</source>. <year>2018</year>;<volume>41</volume>:<fpage>197</fpage>&#x2013;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-018-0136-9</pub-id><pub-id pub-id-type="pmid">29350350</pub-id></mixed-citation></ref>
<ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mil&#x00E1;nkovics</surname><given-names>I</given-names></name><name><surname>Schuler</surname><given-names>&#x00C1;</given-names></name><name><surname>K&#x00E1;mory</surname><given-names>E</given-names></name><name><surname>Cs&#x00F3;kay</surname><given-names>B</given-names></name><name><surname>Fodor</surname><given-names>F</given-names></name><name><surname>Somogyi</surname><given-names>C</given-names></name><etal/></person-group> <article-title>Molecular and clinical analysis of patients with classic and Duarte galactosemia in western Hungary.</article-title> <source>Wien Klin Wochenschr</source>. <year>2010</year>;<volume>122</volume>:<fpage>95</fpage>&#x2013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1007/s00508-010-1311-7</pub-id><pub-id pub-id-type="pmid">20213376</pub-id></mixed-citation></ref>
<ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viggiano</surname><given-names>E</given-names></name><name><surname>Marabotti</surname><given-names>A</given-names></name><name><surname>Burlina</surname><given-names>AP</given-names></name><name><surname>Cazzorla</surname><given-names>C</given-names></name><name><surname>D&#x2019;Apice</surname><given-names>MR</given-names></name><name><surname>Giordano</surname><given-names>L</given-names></name><etal/></person-group> <article-title>Clinical and molecular spectra in galactosemic patients from neonatal screening in northeastern Italy: Structural and functional characterization of new variations in the galactose-1-phosphate uridyltransferase (GALT) gene.</article-title> <source>Gene</source>. <year>2015</year>;<volume>559</volume>:<fpage>112</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2015.01.013</pub-id><pub-id pub-id-type="pmid">25592817</pub-id></mixed-citation></ref>
<ref id="r46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bech</surname><given-names>LF</given-names></name><name><surname>Donneborg</surname><given-names>ML</given-names></name><name><surname>Lund</surname><given-names>AM</given-names></name><name><surname>Ebbesen</surname><given-names>F</given-names></name></person-group>. <article-title>Extreme neonatal hyperbilirubinemia, acute bilirubin encephalopathy, and kernicterus spectrum disorder in children with galactosemia.</article-title> <source>Pediatr Res</source>. <year>2018</year>;<volume>84</volume>:<fpage>228</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1038/s41390-018-0066-0</pub-id><pub-id pub-id-type="pmid">29892033</pub-id></mixed-citation></ref>
<ref id="r47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waisbren</surname><given-names>SE</given-names></name><name><surname>Potter</surname><given-names>NL</given-names></name><name><surname>Gordon</surname><given-names>CM</given-names></name><name><surname>Green</surname><given-names>RC</given-names></name><name><surname>Greenstein</surname><given-names>P</given-names></name><name><surname>Gubbels</surname><given-names>CS</given-names></name><etal/></person-group> <article-title>The adult galactosemic phenotype.</article-title> <source>J Inherit Metab Dis</source>. <year>2012</year>;<volume>35</volume>:<fpage>279</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-011-9372-y</pub-id><pub-id pub-id-type="pmid">21779791</pub-id></mixed-citation></ref>
<ref id="r48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timmers</surname><given-names>I</given-names></name><name><surname>van der Korput</surname><given-names>LD</given-names></name><name><surname>Jansma</surname><given-names>BM</given-names></name><name><surname>Rubio-Gozalbo</surname><given-names>ME</given-names></name></person-group>. <article-title>Grey matter density decreases as well as increases in patients with classic galactosemia: A voxel-based morphometry study.</article-title> <source>Brain Res</source>. <year>2016</year>;<volume>1648</volume>:<fpage>339</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2016.08.005</pub-id><pub-id pub-id-type="pmid">27502028</pub-id></mixed-citation></ref>
<ref id="r49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermans</surname><given-names>ME</given-names></name><name><surname>Welsink-Karssies</surname><given-names>MM</given-names></name><name><surname>Bosch</surname><given-names>AM</given-names></name><name><surname>Oostrom</surname><given-names>KJ</given-names></name><name><surname>Geurtsen</surname><given-names>GJ</given-names></name></person-group>. <article-title>Cognitive functioning in patients with classical galactosemia: A systematic review.</article-title> <source>Orphanet J Rare Dis</source>. <year>2019</year>;<volume>14</volume>:<fpage>226</fpage>. <pub-id pub-id-type="doi">10.1186/s13023-019-1215-1</pub-id><pub-id pub-id-type="pmid">31627760</pub-id></mixed-citation></ref>
<ref id="r50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>AM</given-names></name></person-group>. <article-title>Classical galactosaemia revisited.</article-title> <source>J Inherit Metab Dis</source>. <year>2006</year>;<volume>29</volume>:<fpage>516</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-006-0382-0</pub-id><pub-id pub-id-type="pmid">16838075</pub-id></mixed-citation></ref>
<ref id="r51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welling</surname><given-names>L</given-names></name><name><surname>Bernstein</surname><given-names>LE</given-names></name><name><surname>Berry</surname><given-names>GT</given-names></name><name><surname>Burlina</surname><given-names>AB</given-names></name><name><surname>Eyskens</surname><given-names>F</given-names></name><name><surname>Gautschi</surname><given-names>M</given-names></name><etal/></person-group> <article-title>International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up.</article-title> <source>J Inherit Metab Dis</source>. <year>2017</year>;<volume>40</volume>:<fpage>171</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-016-9990-5</pub-id><pub-id pub-id-type="pmid">27858262</pub-id></mixed-citation></ref>
<ref id="r52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakur</surname><given-names>M</given-names></name><name><surname>Feldman</surname><given-names>G</given-names></name><name><surname>Puscheck</surname><given-names>EE</given-names></name></person-group>. <article-title>Primary ovarian insufficiency in classic galactosemia: current understanding and future research opportunities.</article-title> <source>J Assist Reprod Genet</source>. <year>2018</year>;<volume>35</volume>:<fpage>3</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1007/s10815-017-1039-7</pub-id><pub-id pub-id-type="pmid">28932969</pub-id></mixed-citation></ref>
<ref id="r53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fridovich-Keil</surname><given-names>JL</given-names></name><name><surname>Gubbels</surname><given-names>CS</given-names></name><name><surname>Spencer</surname><given-names>JB</given-names></name><name><surname>Sanders</surname><given-names>RD</given-names></name><name><surname>Land</surname><given-names>JA</given-names></name><name><surname>Rubio-Gozalbo</surname><given-names>E</given-names></name></person-group>. <article-title>Ovarian function in girls and women with GALT-deficiency galactosemia.</article-title> <source>J Inherit Metab Dis</source>. <year>2011</year>;<volume>34</volume>:<fpage>357</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-010-9221-4</pub-id><pub-id pub-id-type="pmid">20978943</pub-id></mixed-citation></ref>
<ref id="r54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>FR</given-names></name><name><surname>Kogut</surname><given-names>MD</given-names></name><name><surname>Donnell</surname><given-names>GN</given-names></name><name><surname>Goebelsmann</surname><given-names>U</given-names></name><name><surname>March</surname><given-names>C</given-names></name><name><surname>Koch</surname><given-names>R</given-names></name></person-group>. <article-title>Hypergonadotropic hypogonadism in female patients with galactosemia.</article-title> <source>N Engl J Med</source>. <year>1981</year>;<volume>304</volume>:<fpage>994</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM198104233041702</pub-id><pub-id pub-id-type="pmid">6782485</pub-id></mixed-citation></ref>
<ref id="r55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Erven</surname><given-names>B</given-names></name><name><surname>Welling</surname><given-names>L</given-names></name><name><surname>Calcar</surname><given-names>SC</given-names></name><name><surname>Doulgeraki</surname><given-names>A</given-names></name><name><surname>Eyskens</surname><given-names>F</given-names></name><name><surname>Gribben</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Bone health in classic galactosemia: Systematic review and meta-analysis.</article-title> <source>JIMD.</source> <year>2017</year>;<volume>35</volume>:<fpage>87</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1007/8904_2016_28</pub-id><pub-id pub-id-type="pmid">27995581</pub-id></mixed-citation></ref>
<ref id="r56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubio-Gozalbo</surname><given-names>ME</given-names></name></person-group>. <article-title>Bone mineral density in patients with classic galactosaemia.</article-title> <source>Arch Dis Child</source>. <year>2002</year>;<volume>87</volume>:<fpage>57</fpage>&#x2013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1136/adc.87.1.57</pub-id><pub-id pub-id-type="pmid">12089126</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
